<SEC-DOCUMENT>0001193125-23-277893.txt : 20231115
<SEC-HEADER>0001193125-23-277893.hdr.sgml : 20231115
<ACCEPTANCE-DATETIME>20231115161114
ACCESSION NUMBER:		0001193125-23-277893
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20231115
DATE AS OF CHANGE:		20231115

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Ovid Therapeutics Inc.
		CENTRAL INDEX KEY:			0001636651
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				465270895
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-275307
		FILM NUMBER:		231410673

	BUSINESS ADDRESS:	
		STREET 1:		441 NINTH AVENUE, 14TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10001
		BUSINESS PHONE:		212-776-4381

	MAIL ADDRESS:	
		STREET 1:		441 NINTH AVENUE, 14TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10001
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d561116d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(5)<BR>Registration No. 333-275307 </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g561116g05d52.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>$75,000,000 </B></P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:14pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered
into a sales agreement with Cowen and Company, LLC, or TD Cowen, dated November&nbsp;12, 2020, or the sales agreement, relating to shares of our common stock offered by this prospectus. In accordance with the terms of the sales agreement and as of
the date of this prospectus, we may offer and sell shares of our common stock having an aggregate offering price of up to $75,000,000 from time to time through TD Cowen. </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The Nasdaq Global Select Market, or Nasdaq, under the symbol &#147;OVID.&#148; On October&nbsp;31, 2023, the
last reported sale price of our common stock was $3.55 per share.<B> </B> </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of our common stock, if any, under this prospectus may be
made in sales deemed to be an &#147;at the market offering&#148; as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, or the Securities Act. TD Cowen is not required to sell any specific number or dollar amount of
securities, but will act as a sales agent using commercially reasonable efforts consistent with its normal trading and sales practices, on mutually agreed terms between TD Cowen and us. </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The compensation to TD Cowen for sales of common stock sold pursuant to the sales agreement will be up to 3.0% of the gross proceeds of any
shares of common stock sold under the sales agreement. In connection with the sale of the common stock on our behalf, TD Cowen will be deemed to be an &#147;underwriter&#148; within the meaning of the Securities Act and the compensation of TD Cowen
will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to TD Cowen with respect to certain liabilities, including liabilities under the Securities Act or the Securities Exchange
Act of 1934, as amended, or the Exchange Act. </P> <P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:14pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Investing in
our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading &#147;<A HREF="#tocb561116_3">Risk Factors</A>&#148; on page&nbsp;S-7 of this prospectus and under similar headings in
the other documents that are incorporated by reference into this prospectus. </B></P> <P STYLE="margin-top:14pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor
any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>TD Cowen </B></P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of
this prospectus is November 15, 2023. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tocb561116_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-i</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tocb561116_2">SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tocb561116_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tocb561116_4">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tocb561116_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tocb561116_6">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tocb561116_7">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tocb561116_8">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tocb561116_9">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tocb561116_10">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tocb561116_11">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tocb561116_12">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-23</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tocb561116_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This sales agreement prospectus is a part of a registration statement that we have filed on Form <FONT STYLE="white-space:nowrap">S-3</FONT>
with the U.S. Securities and Exchange Commission, or the SEC, utilizing a &#147;shelf&#148; registration process. We may offer shares of our common stock having an aggregate offering price of up to $75,000,000 from time to time under this sales
agreement prospectus through TD Cowen acting as our agent and on terms to be determined by market conditions at the time of the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus relates to the offering of our common stock. Before buying any of the common stock that we are offering, we urge you to
carefully read this prospectus, together with the information incorporated by reference as described under the headings &#147;Where You Can Find More Information&#148; and &#147;Incorporation of Certain Information by Reference&#148; in this
prospectus. These documents contain important information that you should consider when making your investment decision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus
describes the terms of this common stock offering and also adds to and updates information contained in the documents incorporated by reference herein. To the extent there is a conflict between the information contained in this prospectus and the
information contained in any document incorporated by reference into this prospectus that was filed with the SEC before the date of this prospectus, you should rely on the information in this prospectus; provided that if any statement in one of
these documents is inconsistent with a statement in another document having a later date&#151;for example, a document incorporated by reference into this prospectus&#151;the statement in the document having the later date modifies or supersedes the
earlier statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the information contained in or incorporated by reference in this prospectus and in any free
writing prospectus that we have authorized for use in connection with this offering. We have not, and the sales agent has not, authorized anyone to provide you with different information. If anyone provides you with different or inconsistent
information, you should not rely on it. We are not, and the sales agent is not, making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this
prospectus, the documents incorporated by reference in this prospectus, and in any free writing prospectus that we have authorized for use in connection with this offering, is accurate only as of the date of those respective documents. Our business,
financial condition, results of operations and prospects may have changed since those dates. You should read this prospectus, the documents incorporated by reference in this prospectus, and any free writing prospectus that we have authorized for use
in connection with this offering, in their entirety before making an investment decision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context indicates otherwise,
references in this prospectus to &#147;Ovid,&#148; &#147;the Company,&#148; &#147;we,&#148; &#147;us,&#148; &#147;our&#148; and similar references refer to Ovid Therapeutics Inc. and its wholly owned subsidiaries. Our name &#147;Ovid
Therapeutics&#148; the Ovid logo and other trademarks, trade names or service marks of Ovid Therapeutics Inc. appearing in this prospectus are the property of Ovid Therapeutics Inc. All other trademarks, trade names and service marks appearing in
this prospectus are the property of their respective owners. Solely for convenience, the trademarks and trade names in this prospectus are referred to without the <SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and <SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP> symbols, but such references should not be construed as any indicator that their respective owners will not assert their rights thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tocb561116_2"></A>SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights certain information about us, this offering and selected information contained elsewhere in or incorporated by
reference into this prospectus. This summary is not complete and does not contain all of the information that you should consider before deciding whether to invest in our common stock. For a more complete understanding of our company and this
offering, we encourage you to read and consider carefully the more detailed information in this prospectus, including the information incorporated by reference in this prospectus, and the information included in any free writing prospectus that we
have authorized for use in connection with this offering, including the information under the heading &#147;Risk Factors&#148; in this prospectus on page S-7 and in the documents incorporated by reference into this prospectus. </I></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Company Overview </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are
a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders in a manner that is scientifically driven and patient focused. We have set out to be a leader in the field
of rare epilepsies and intractable neurological diseases with seizure symptoms. Our differentiated pipeline of potential small molecule medicines has produced four unique anti-seizure programs to date, three of which we are actively developing, and
the fourth, which we co-developed, was subsequently repurchased by Takeda Company Limited (&#147;Takeda&#148;). This pipeline was curated using an integrated and disciplined approach to business development, research, and clinical development. All
of the programs in our pipeline act upon either extrinsic or intrinsic factors modulating neuronal hyperexcitability, which we believe underlies seizures and other neurological conditions. Our management team has substantial understanding of rare
disease and neurological conditions gained from the management team&#146;s collective experience and contributions to the development and launch of more than 25 approved medicines in their respective careers prior to joining Ovid. Such experience
includes many approved anti-seizure medicines. Our knowledge of the underlying biologic targets driving hyperexcitability and the pathology of refractory epilepsies has produced clinical-stage development programs, the most advanced of which was
soticlestat, which was repurchased by Takeda in 2021 and is being actively studied by Takeda in two pivotal Phase 3 trials in Lennox-Gastaut syndrome and Dravet syndrome. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Over time, we have built a replicable and scalable approach to develop small molecule candidates, which begins with conducting animal disease
models and toxicology studies in the pre-clinic to build evidence and confidence before moving into the clinic. Initially, we are pursuing therapeutic assets for rare epilepsies and seizure disorders as they can leverage cost-efficient and
accelerated development programs and they can be evaluated with concrete and measurable endpoints such as seizures and electroencephalogram (EEG) readings. In addition to seizures, if successfully developed and marketed, we intend to explore our
pipeline assets for broader neurologic indications caused by neuronal hyperexcitabilty, as applicable. Our cohesive focus in rare epilepsies and seizures reinforces our belief that we can develop and produce multiple novel medicines, scale our
infrastructure, and thereby succeed in our mission. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Pipeline </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the status and mechanism of action of our drug candidates:<B>&nbsp;</B> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g561116g10k06.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Associated with Our Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is subject to numerous risks. You should read these risks before you invest in our securities. In particular, our risks include,
but are not limited to, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Historically, we have incurred significant operating losses and expect to continue to incur substantial operating
losses for the foreseeable future and may never achieve or maintain profitability. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our operating history may make it difficult to evaluate the success of our business to date and to assess our
future viability. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We will require additional capital to finance our operations, which may not be available on acceptable terms, if
at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate certain of our drug development efforts or other operations. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are early in our development efforts of our current drug candidates and all our drug candidates are in Phase 1
clinical trials or preclinical development. If we are unable to successfully develop, receive regulatory approval for and commercialize our drug candidates, or successfully develop any other drug candidates, or experience significant delays in doing
so, our business will be harmed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have not generated any product revenue to date. Our future success is dependent on the successful clinical
development, regulatory approval and commercialization of our current and future drug candidates. If we, or our licensees, are not able to obtain the required regulatory approvals, we, or our licensees, will not be able to commercialize our drug
candidates, and our ability to generate revenue will be adversely affected. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Because the results of preclinical studies or earlier clinical trials are not necessarily predictive of future
results, our drug candidates may not have favorable results in planned or future preclinical studies or clinical trials, or may not receive regulatory approval. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Interim topline and preliminary results from our clinical trials that we announce or publish from time to time
may change as more patient data become available and are subject to audit and verification procedures, which could result in material changes in the final data. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Preclinical studies and clinical trials are very expensive, time-consuming and difficult to design and implement
and involve uncertain outcomes. Further, we may encounter substantial delays in our clinical trials or we may fail to demonstrate safety and efficacy in our preclinical studies and clinical trials to the satisfaction of applicable regulatory
authorities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are not successful in discovering, developing and commercializing additional drug candidates, our ability
to expand our business and achieve our strategic objectives would be impaired. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our drug candidates may cause undesirable side effects or have other properties that could delay or prevent their
regulatory approval, limit the commercial potential or result in significant negative consequences following any potential marketing approval. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Even if our current or future drug candidates receive marketing approval, they may fail to achieve market
acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Under the royalty, license and termination agreement with Takeda, we are entitled to receive royalty and
milestone payments in connection with the development and commercialization of soticlestat. If Takeda fails to progress, delays or discontinues the development of soticlestat, or if soticlestat fails to achieve market acceptance or commercial
success, we may not receive some or all of such payments, which would materially harm our business. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our relationships with customers, physicians, and third-party payors may be subject, directly or indirectly, to
federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and security laws, and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face
substantial penalties. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Coverage and adequate reimbursement may not be available for our current or any future drug candidates, which
could make it difficult for us to sell profitably, if approved. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to obtain and maintain patent protection for our current or any future drug candidates, or if
the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may be involved in lawsuits to protect or enforce our patents, the patents of our licensors or our other
intellectual property rights, which could be expensive, time consuming and unsuccessful. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We do not have our own manufacturing capabilities and will rely on third parties to produce clinical and
commercial supplies of our current and any future drug candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We intend to rely on third parties to conduct, supervise and monitor our preclinical studies and clinical trials,
and if those third parties perform in an unsatisfactory manner, it may harm our business. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may need to expand our organization, and we may experience difficulties in managing this growth, which could
disrupt our operations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may be subject to numerous and varying privacy and security laws, and our failure to comply could result in
penalties and reputational damage. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated in Delaware in April 2014. Our principal executive offices are located at 441 Ninth Avenue, 14th Floor, New York, New York
10001 and our telephone number is (646) <FONT STYLE="white-space:nowrap">661-7661.</FONT> Our common stock is listed on Nasdaq under the symbol &#147;OVID.&#148; Our corporate website address is www.ovidrx.com. Information contained on or accessible
through our website is not incorporated by reference into this prospectus. We have included our website in this prospectus solely as an inactive textual reference. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being a Smaller Reporting Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a smaller reporting company as defined in the Securities Exchange Act of 1934, as amended, or the Exchange Act. We may take advantage of
certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as (i)&nbsp;our voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT
STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million measured on the last business day of our second fiscal quarter or (ii)&nbsp;our annual revenue is less than $100.0&nbsp;million during the most recently completed
fiscal year and our voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million measured on the last business day of our second fiscal
quarter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a smaller reporting company, we are permitted to comply with scaled-back disclosure obligations in our SEC filings compared
to other issuers, including with respect to disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We have elected to adopt the accommodations available to smaller reporting companies, including but not
limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure obligations regarding our executive compensation arrangements; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">being permitted to provide only two years of audited financial statements, in addition to any required unaudited
interim financial statements, with correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common Stock Offered By Us </P></TD>
<TD>Shares of our common stock having an aggregate offering price of up to $75,000,000. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common Stock to be Outstanding After This Offering </P></TD>
<TD>Up to 91,807,311 shares (as more fully described in the notes following this table), assuming sales of 21,126,760 shares of our common stock in this offering at an assumed offering price of $3.55 per share, the last reported sale price of our
common stock on Nasdaq on October&nbsp;31, 2023. The actual number of shares issued will vary depending on the sales price under this offering. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Manner of Offering </P></TD>
<TD>&#147;At the market offering&#148; that may be made from time to time through our sales agent, TD Cowen. See &#147;Plan of Distribution&#148; on page<B> </B>S-21. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of Proceeds </P></TD>
<TD>We currently intend to use the net proceeds from this offering primarily to fund the research and development of our drug candidates, acquire or invest in businesses, products or technologies that are complementary to our own, although we have
no current plans, commitments or agreements with respect to any acquisitions as of the date of this prospectus, and for working capital and general corporate purposes. See &#147;Use of Proceeds&#148; on page S-11 of this prospectus.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk Factors </P></TD>
<TD>Investing in our common stock involves significant risks. See &#147;Risk Factors&#148; on page S-7 <B></B>of this prospectus, and under similar headings in other documents incorporated by reference into this prospectus. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Nasdaq Global Select Market symbol </P></TD>
<TD>&#147;OVID&#148; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding immediately after this offering is based on
70,680,551 shares of our common stock outstanding as of September&nbsp;30, 2023, and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">15,164,871 shares of our common stock issuable upon the exercise of stock options outstanding as of
September&nbsp;30, 2023 under our 2014 Stock Plan, as amended, or 2014 Plan, and our 2017 Equity Incentive Plan, or 2017 Plan, at a weighted average exercise price of $3.86 per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">4,371,869 shares of common stock reserved for future issuance under our 2017 Plan as of September&nbsp;30, 2023,
plus any additional shares of our common stock that may become available under our 2017 Plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">352,846 shares of our common stock reserved for issuance under our 2017 Employee Stock Purchase Plan, or ESPP, as
of September&nbsp;30, 2023, as well as any future increases in the number of shares of our common stock reserved for issuance under the ESPP; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,250,000 shares of our common stock issuable upon the conversion of 1,250 shares of our Series A convertible
preferred stock, or the Series A preferred stock, outstanding as of September&nbsp;30, 2023. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise
indicated, the information in this prospectus assumes no exercise of the outstanding stock options and no conversion of the outstanding Series A preferred stock. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tocb561116_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Investing in our securities involves a high degree of risk. Before deciding whether to invest in our common stock, you should carefully
consider the risks described below and those discussed under the section titled &#147;Risk Factors&#148; contained in our Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K&nbsp;for</FONT> the December&nbsp;31, 2022 and in our
Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended September&nbsp;30, 2023, as updated by our subsequent filings under the Exchange Act and other documents, which are incorporated by reference into this
prospectus, before deciding whether to purchase any of the securities being registered pursuant to the registration statement of which this prospectus is a part. Each of the risk factors could adversely affect our business, results of operations,
financial condition and cash flows, as well as adversely affect the value of an investment in our securities, and the occurrence of any of these risks might cause you to lose all or part of your investment. Additional risks not presently known to us
or that we currently believe are immaterial may also significantly impair our business operations. Please also read carefully the section below titled &#147;Special Note Regarding Forward-Looking Statements.&#148; </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to this Offering </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our
management has broad discretion in the use proceeds from this offering in ways with which you do not agree and in ways that may impair the value of your investment. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently intend to use the net proceeds from this offering primarily to fund the development of our drug candidates and for working capital
and general corporate purposes. We may also use the net proceeds from this offering for <FONT STYLE="white-space:nowrap">certain&nbsp;pre-commercialization&nbsp;activities</FONT> and to acquire or invest in businesses, products or technologies that
are complementary to our own, although we have no current plans, commitments or agreements with respect to any acquisitions as of the date of this prospectus. Pending the use of net proceeds from this offering as further described in the section
titled &#147;Use of Proceeds,&#148; we intend to invest the net proceeds in short-term, investment-grade, interest bearing obligations, certificates of deposit or direct or guaranteed obligations of the United States. Our management has broad
discretion as to the use of these proceeds and you will be relying on the judgment of our management regarding the application of these proceeds. We might apply these proceeds in ways with which you do not agree, or in ways that do not yield a
favorable return. If our management applies these proceeds in a manner that does not yield a significant return, if any, on our investment of these net proceeds, it could compromise our ability to pursue our growth strategy and adversely affect the
market price of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If you purchase shares of common stock in this offering, you may suffer immediate and substantial
dilution of your investment. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The price per share of our common stock in this offering may exceed the net tangible book value per
share of our common stock outstanding prior to this offering. Therefore, if you purchase shares of our common stock in this offering, you may pay a price per share that substantially exceeds our net tangible book value per share after this offering.
To the extent shares are issued under outstanding options at exercise prices lower than the price of our common stock in this offering, you will incur further dilution. See the section entitled &#147;<I>Dilution</I>&#148; below for a more detailed
illustration of the dilution you would incur if you participate in this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>You may experience future dilution as a result of
future equity offerings. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will require more capital to pursue our preclinical and clinical activities, regulatory approval and
the commercialization of our current or future drug candidates. In addition, we may also choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future
operating plans. To raise additional capital, we may in the future offer additional shares of our common stock or other securities convertible into or exchangeable for our common stock at prices that may not be the same as the price per share in
this offering. We may sell shares or other securities in any other offering at a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
price per share that is less than the price per share paid by investors in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing
stockholders. The price per share at which we sell additional shares of our common stock, or securities convertible or exchangeable into common stock, in future transactions may be higher or lower than the price per share paid by investors in this
offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>It is not possible to predict the actual number of shares we will sell under the sales agreement, or the gross proceeds
resulting from those sales. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to certain limitations in the sales agreement and compliance with applicable law, we have the
discretion to deliver instruction to TD Cowen to sell shares of our common stock at any time throughout the term of the sales agreement. The number of shares that are sold through TD Cowen after our instruction will fluctuate based on a number of
factors, including the market price of our common stock during the sales period, the limits we set with TD Cowen in any instruction to sell shares, and the demand for our common stock during the sales period. Because the price per share of each
share sold will fluctuate during this offering, it is not currently possible to predict the number of shares that will be sold or the gross proceeds to be raised in connection with those sales. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>The common stock offered hereby will be sold in &#147;at the market offerings,&#148; and investors who buy shares at different times
will likely pay different prices. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investors who purchase shares in this offering at different times will likely pay different
prices, and so may experience different levels of dilution and different outcomes in their investment results. We will have discretion, subject to market demand, to vary the timing, prices, and numbers of shares sold in this offering. In addition,
subject to the final determination by our board of directors, there is no minimum or maximum sales price for shares to be sold in this offering. Investors may experience a decline in the value of the shares they purchase in this offering as a result
of sales made at prices lower than the prices they paid. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tocb561116_4"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and the documents incorporated by reference contain forward-looking statements. These are based on our management&#146;s
current beliefs, expectations and assumptions about future events, conditions and results and on information currently available to us. Discussions containing these forward-looking statements may be found, among other places, in the sections titled
&#147;Business,&#148; &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; incorporated by reference from our most recent Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> and our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> as well as any amendments thereto, filed with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some cases, you can identify forward-looking statements by terminology such as &#147;anticipate,&#148; &#147;believe,&#148;
&#147;could,&#148; &#147;estimate,&#148; &#147;expects,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;should,&#148; &#147;will,&#148; &#147;would&#148; or the
negative or plural of those terms, and similar expressions intended to identify statements about the future, although not all forward-looking statements contain these words. These statements involve known and unknown risks, uncertainties and other
factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any statements in this prospectus, or incorporated herein, about our expectations, beliefs, plans, objectives, assumptions or future events or
performance are not historical facts and are forward-looking statements. Within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, these forward-looking
statements include statements regarding: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify additional novel compounds with significant commercial potential to acquire or <FONT
STYLE="white-space:nowrap">in-license;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> additional drug
candidates on reasonable terms; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding expenses, future revenue including any royalty or milestone payments, capital
requirements and needs for additional financing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain regulatory approval of our current and future drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the timing of clinical trials and potential regulatory filings; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, timing, progress and results of our current and future preclinical studies and clinical trials
and our research and development programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the potential market size and the rate and degree of market acceptance of such drug
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to fund our working capital requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the implementation of our business model and strategic plans for our business and drug candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments or disputes concerning our intellectual property or other proprietary rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain and establish collaborations or obtain additional funding; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding government and third-party payor coverage and reimbursement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to compete in the markets we serve; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of government laws and regulations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments relating to our competitors and our industry; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of geopolitical tensions, including war or the perception that hostilities may be imminent, adverse
global economic conditions, terrorism, natural disasters or public health crises on our </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
operations, research and development and clinical trials and potential disruption in the operations and business of third parties and collaborators with whom we conduct business.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should refer to the &#147;Risk Factors&#148; section contained in this prospectus and any related free writing
prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus, for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by
our forward-looking statements. Given these risks, uncertainties and other factors, many of which are beyond our control, we cannot assure you that the forward-looking statements in this prospectus will prove to be accurate, and you should not place
undue reliance on these forward-looking statements. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not
regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to revise any forward-looking
statements to reflect events or developments occurring after the date of this prospectus, even if new information becomes available in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tocb561116_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue and sell shares of our common stock having aggregate sales proceeds of up to $75.0&nbsp;million from time to time. Because there
is no minimum offering amount required as a condition to close this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. There can be no assurance that we will sell any shares
under or fully utilize the sales agreement with TD Cowen as a source of financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently intend to use the net proceeds from this
offering primarily to fund the research and development of our drug candidates, acquire or invest in businesses, products or technologies that are complementary to our own, although we have no current plans, commitments or agreements with respect to
any acquisitions as of the date of this prospectus, and for working capital and general corporate purposes. Pending the use of net proceeds, we intend to invest the net proceeds in short-term, investment-grade, interest bearing obligations,
certificates of deposit or direct or guaranteed obligations of the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tocb561116_6"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our net tangible book value as of September&nbsp;30, 2023 was $101.1 million, or $1.43 per share. Net tangible book value per share is
determined by dividing our total tangible assets, less total liabilities, by the number of shares of our common stock outstanding as of September&nbsp;30, 2023. Dilution with respect to net tangible book value per share represents the difference
between the amount per share paid by investors purchasing shares of common stock in this offering and the net tangible book value per share of our common stock immediately after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our pro forma net tangible book value as of September&nbsp;30, 2023 was $131.0 million, or $1.85 per share. Pro forma net tangible book value
per share is determined by dividing our total tangible assets, less total liabilities, by the number of shares of our common stock outstanding as of September&nbsp;30, 2023, after giving effect to the receipt of approximately $30.0&nbsp;million
pursuant to the Purchase and Sale Agreement entered into with Ligand Pharmaceuticals Incorporated subsequent to September&nbsp;30, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After giving effect to the sale of $75.0&nbsp;million of shares of our common stock in this offering at an assumed offering price of $3.55 per
share, the last reported sale price of our common stock on Nasdaq on October&nbsp;31, 2023, and after deducting commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of September&nbsp;30,
2023 would have been approximately $204.0 million, or $2.24 per share. This represents an immediate increase in net tangible book value of $0.38 per share to existing stockholders and immediate dilution in net tangible book value of $1.31 per share
to investors purchasing our common stock in this offering. The following table illustrates this dilution on a per share basis: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical net tangible book value per share of as September&nbsp;30, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma increase in net tangible book value per share as of September&nbsp;30, 2023 attributable
to the pro forma transaction described above</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net tangible book value per share as of September&nbsp;30, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in net tangible book value per share attributable to this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma as adjusted net tangible book value per share as of September&nbsp;30, 2023, after
giving effect to this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above discussion and table are based on 70,680,551 shares of our common stock outstanding as of
September&nbsp;30, 2023, and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">15,164,871 shares of our common stock issuable upon the exercise of stock options outstanding as of
September&nbsp;30, 2023 under our 2014 Stock Plan, as amended, or 2014 Plan, and our 2017 Equity Incentive Plan, or 2017 Plan, at a weighted average exercise price of $3.86 per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">352,846 shares of common stock reserved for future issuance under our 2017 Plan as of September 30, 2023, plus
any additional shares of our common stock that may become available under our 2017 Plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">416,607 shares of our common stock reserved for issuance under our 2017 Employee Stock Purchase Plan, or ESPP as
of September 30, 2023, as well as any future increases in the number of shares of our common stock reserved for issuance under the ESPP; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,250,000 shares of our common stock issuable upon the conversion of 1,250 shares of our Series A convertible
preferred stock, or the Series A preferred stock, outstanding as of September&nbsp;30, 2023. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above illustration of dilution per share to investors participating in this offering
assumes no exercise of outstanding options to purchase our common stock and no conversion of the outstanding Series A preferred stock. To the extent that outstanding options outstanding as of September&nbsp;30, 2023 have been or may be exercised or
other shares of common stock are issued, including shares of our common stock issuable upon conversion of our outstanding Series A preferred stock, investors purchasing our common stock in this offering may experience further dilution. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tocb561116_7"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following description of our capital stock and provisions of our amended and restated certificate of incorporation and amended and
restated bylaws are summaries. You should also refer to the amended and restated certificate of incorporation and the amended and restated bylaws, which are filed as exhibits to the registration statement of which this prospectus is part. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our amended and restated
certificate of incorporation we are authorized to issue up to 125,000,000 shares of common stock, par value $0.001 per share, and 10,000,000 shares of preferred stock, par value $0.001 per share. Our board of directors has designated 10,000 shares
of preferred stock as Series A Convertible Preferred Stock, or Series A Preferred Stock, and may establish the rights and preferences of other series of preferred stock from time to time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each holder of common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders. The affirmative vote
of holders of at least 66 2/3% of the voting power of all of the then-outstanding shares of capital stock, voting as a single class, will be required to amend certain provisions of our amended and restated certificate of incorporation, including
provisions relating to amending our amended and restated bylaws, the classified board, the size of our board, removal of directors, director liability, vacancies on our board, special meetings, stockholder notices, actions by written consent and
exclusive jurisdiction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to preferences that may apply to any outstanding preferred stock, holders of our common stock are entitled to receive ratably any
dividends that our board of directors may declare out of funds legally available for that purpose on a <FONT STYLE="white-space:nowrap">non-cumulative</FONT> basis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of our
liquidation, dissolution or winding up, holders of our common stock are entitled to share ratably in all assets remaining after payment of liabilities and the liquidation preference of any outstanding preferred stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Rights and Preferences </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of
our common stock have no preemptive, conversion, subscription or other rights, and there are no redemption or sinking fund provisions applicable to our common stock. The rights, preferences and privileges of the holders of our common stock are
subject to and may be adversely affected by the rights of the holders of shares of any series of our preferred stock that we may designate in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to our amended
and restated certificate of incorporation, our board of directors has the authority, without further action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series and to fix the number, rights, preferences,
privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences and sinking fund terms, and the number of shares constituting
any series or the designation of such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
series, any or all of which may be greater than the rights of common stock. The issuance of our preferred stock could adversely affect the voting power of holders of common stock and the
likelihood that such holders will receive dividend payments and payments upon liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change of control or other corporate action, or make
the removal of management more difficult. Additionally, the issuance of preferred stock may have the effect of decreasing the market price of the common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors will fix the designations, voting powers, preferences and rights of each series, as well as the qualifications,
limitations or restrictions thereof, of the preferred stock of each series that we offer under this prospectus and applicable prospectus supplements in the certificate of designation relating to that series. We will file as an exhibit to the
registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of any certificate of designation that describes the terms of the series of preferred stock we are offering
before the issuance of that series of preferred stock. This description will include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title and stated value; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares we are offering; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the liquidation preference per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the purchase price per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dividend rate per share, dividend period and payment dates and method of calculation for dividends;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether dividends will be cumulative or <FONT STYLE="white-space:nowrap">non-cumulative</FONT> and, if
cumulative, the date from which dividends will accumulate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right, if any, to defer payment of dividends and the maximum length of any such deferral period;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the procedures for any auction and remarketing, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provisions for a sinking fund, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provisions for redemption or repurchase, if applicable, and any restrictions on our ability to exercise those
redemption and repurchase rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any listing of the preferred stock on any securities exchange or market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the preferred stock will be convertible into our common stock or other securities of ours, including
depositary shares and warrants, and, if applicable, the conversion period, the conversion price, or how it will be calculated, and under what circumstances it may be adjusted; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the preferred stock will be exchangeable into debt securities, and, if applicable, the exchange period,
the exchange price, or how it will be calculated, and under what circumstances it may be adjusted; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">voting rights, if any, of the preferred stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preemption rights, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on transfer, sale or other assignment, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether interests in the preferred stock will be represented by depositary shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a discussion of any material or special U.S. federal income tax considerations applicable to the preferred stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the relative ranking and preferences of the preferred stock as to dividend rights and rights if we liquidate,
dissolve or wind up our affairs; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any limitations on issuances of any class or series of preferred stock ranking senior to or on a parity with the
series of preferred stock being issued as to dividend rights and rights if we liquidate, dissolve or wind up our affairs; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms, rights, preferences, privileges, qualifications or restrictions of the preferred stock.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Delaware General Corporation Law, or DGCL, which is the law of the state of our incorporation, provides that the
holders of preferred stock will have the right to vote separately as a class (or, in some cases, as a series) on an amendment to our certificate of incorporation if the amendment would change the par value, the powers, preferences or special rights
of the class or series so as to adversely affect the class or series, as the case may be, or, unless the certificate of incorporation provided otherwise, the number of authorized shares of the class. This right is in addition to any voting rights
that may be provided for in the applicable certificate of designation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Series A Convertible Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has designated 10,000 shares of preferred stock as Series A Preferred Stock. The following summary of certain terms and
provisions of our Series A Preferred Stock is subject to, and qualified in its entirety by reference to, the terms and provisions set forth in our certificate of designation of preferences, rights and limitations of Series A Preferred Stock. As of
September&nbsp;30, 2023, we had 1,250 shares of Series A Preferred Stock issued and outstanding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Rank </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Series A Preferred Stock ranks senior to all of our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Conversion </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of the
Series A Preferred Stock is convertible into 1,000 shares of our common stock (subject to adjustment as provided in the related certificate of designation of preferences rights and limitations) at any time at the option of the holder, provided that
the holder will be prohibited, subject to certain exceptions, from converting Series A Preferred Stock into shares of our common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than, at the written
election of the holder, either 9.99% or 14.99% of the total number of shares of our common stock then issued and outstanding, which percentage may be changed at the holder&#146;s election to any other number less than or equal to 19.99% upon 61
days&#146; notice to us; <I>provided</I>, <I>however</I>, that effective 61 days after delivery of such notice, such beneficial ownership limitations shall not be applicable to any holder that beneficially owns at least either 10.0% or 15.0%, as
applicable based on the holder&#146;s initial written election noted above, of the total number of shares of our common stock issued and outstanding immediately prior to delivery of such notice. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation Preference </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the
event of our liquidation, dissolution or winding up, holders of the Series A Preferred Stock will receive a payment equal to $0.001 per share of Series A Preferred Stock before any proceeds are distributed to the holders of our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fundamental Transaction </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon
consummation of a Fundamental Transaction (as defined below) pursuant to which holders of shares of our common stock are entitled to receive securities, cash or property, then upon any subsequent conversion of the Series A Preferred Stock, the
holder thereof shall have the right to receive, in lieu of the right to receive the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shares of our common stock underlying the Series A Preferred Stock, for each share of common stock that it would have otherwise been entitled to receive upon such conversion immediately prior to
the occurrence of such Fundamental Transaction, the same kind and amount of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such
Fundamental Transaction, the holder of one share of our common stock. If holders of our common stock are given a choice as to the securities, cash or property to be received in a Fundamental Transaction, then the holder of the Series A Preferred
Stock shall be given the same choice as to the consideration it receives upon any exercise of the Series A Preferred Stock following such Fundamental Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A &#147;Fundamental Transaction&#148; means: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we effect any merger or consolidation with or into another person or any stock sale to, or other business
combination (including, without limitation, a reorganization, recapitalization, <FONT STYLE="white-space:nowrap">spin-off,</FONT> share exchange or scheme of arrangement) with or into another person (other than such a transaction in which we are the
surviving or continuing entity and our common stock is not exchanged for or converted into other securities, cash or property); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we effect any sale of all or substantially all of our assets in one transaction or a series of related
transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any tender offer or exchange offer (whether by us or another person) is completed pursuant to which more than 50%
of the common stock not held by us or such person is exchanged for or converted into other securities, cash or property; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we effect any reclassification of our common stock or any compulsory share exchange pursuant (other than
specified dividends, subdivisions or combinations) to which our common stock is effectively converted into or exchanged for other securities, cash or property. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares of Series A
Preferred Stock will generally have no voting rights, except as required by law and except that the consent of the holders of a majority of the outstanding shares of Series A Preferred Stock will be required to amend the terms of the Series A
Preferred Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares of Series A Preferred Stock will be entitled to receive dividends at a rate equal to (on an <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">as-if-converted-to-common</FONT></FONT></FONT></FONT> stock basis), and in the same form and manner as, dividends actually paid on shares of common stock.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Redemption </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are not
obligated to redeem or repurchase any shares of Series A Preferred Stock. Shares of Series A Preferred Stock are not otherwise entitled to any redemption rights or mandatory sinking fund or analogous fund provisions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Provisions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;203 of the
Delaware General Corporation Law </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to Section&nbsp;203 of the DGCL, which prohibits a Delaware corporation from
engaging in any business combination with any interested stockholder for a period of three years after the date that such stockholder became an interested stockholder, with the following exceptions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">before such date, the board of directors of the corporation approved either the business combination or the
transaction that resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the
interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding, but not the outstanding voting stock owned by the
interested stockholder, those shares owned (i)&nbsp;by persons who are directors and also officers and (ii)&nbsp;employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the
plan will be tendered in a tender or exchange offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on or after such date, the business combination is approved by the board of directors and authorized at an annual
or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock that is not owned by the interested stockholder. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 defines a &#147;business combination&#148; to include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any merger or consolidation involving the corporation and the interested stockholder; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the
interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any
stock of the corporation to the interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction involving the corporation that has the effect of increasing the proportionate share of the stock
or any class or series of the corporation beneficially owned by the interested stockholder; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other
financial benefits by or through the corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 defines an &#147;interested
stockholder&#148; as an entity or person who, together with the entity or person&#146;s affiliates and associates, beneficially owns, or is an affiliate or associate of the corporation and within three years prior to the time of determination of
interested stockholder status did own, 15% or more of the outstanding voting stock of the corporation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amended and Restated Certificate of
Incorporation and Amended and Restated Bylaws </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Among other things, our amended and restated certificate of incorporation and
amended and restated bylaws: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">permit our board of directors to issue up to 10,000,000 shares of preferred stock, with any rights, preferences
and privileges as they may designate, including the right to approve an acquisition or other change in control; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that the authorized number of directors may be changed only by resolution of our board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that our board of directors are classified into three classes of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that, subject to the rights of any series of preferred stock to elect directors, directors may only be
removed for cause, which removal may be effected, subject to any limitation imposed by law, by the holders of at least a majority of the voting power of all of our then-outstanding shares of the capital stock entitled to vote generally at an
election of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be
filled by the affirmative vote of a majority of directors then in office, even if less than a quorum; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require that any action to be taken by our stockholders must be effected at a duly called annual or special
meeting of stockholders and not be taken by written consent or electronic transmission; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates
for election as directors at a meeting of stockholders must provide advance notice in writing, and also specify requirements as to the form and content of a stockholder&#146;s notice; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that special meetings of our stockholders may be called only by the chairman of our board of directors,
our chief executive officer or president or by our board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not provide for cumulative voting rights, therefore allowing the holders of a majority of the shares of common
stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amendment of any of these provisions would require approval by the holders of at least 66 2/3% of the voting power of all of our
then-outstanding common stock entitled to vote generally in the election of directors, voting together as a single class. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The combination
of these provisions will make it more difficult for our existing stockholders to replace our board of directors as well as for another party to obtain control of us by replacing our board of directors. Because our board of directors has the power to
retain and discharge our officers, these provisions could also make it more difficult for existing stockholders or another party to effect a change in management. In addition, the authorization of undesignated preferred stock makes it possible for
our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change our control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions are intended to enhance the likelihood of continued stability in the composition of our board of directors and its policies
and to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to reduce our vulnerability to hostile takeovers and to discourage certain tactics that may be used in proxy fights. However, such
provisions could have the effect of discouraging others from making tender offers for our shares and may have the effect of delaying changes in our control or management. As a consequence, these provisions may also inhibit fluctuations in the market
price of our stock that could result from actual or rumored takeover attempts. We believe that the benefits of these provisions, including increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited
proposal to acquire or restructure our company, outweigh the disadvantages of discouraging takeover proposals, because negotiation of takeover proposals could result in an improvement of their terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Choice of Forum </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and
restated certificate of incorporation provides that unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall (or, if and only if the Court of Chancery of the State of Delaware lacks
subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware), the Court of Chancery of the State
of Delaware will be the exclusive forum for (1)&nbsp;any derivative action or proceeding brought on our behalf, (2)&nbsp;any action or proceeding commenced by any of our stockholders (including any class action) asserting a breach of fiduciary duty
owed, or other wrongdoing, by any director, officer, employee or agent to us or our stockholders, (3)&nbsp;any action or proceeding commenced by any of our stockholders (including any class action) asserting a claim against us arising pursuant to
the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws, (4)&nbsp;any action or proceeding commenced by any of our stockholders (including any class action) to interpret, apply, enforce or determine the
validity of our amended and restated certificate of incorporation or our amended and restated bylaws, or (5)&nbsp;any action or proceeding commenced by any of our stockholders (including any class action) asserting a claim against us that is
governed by the internal affairs doctrine. The enforceability of similar choice of forum provisions in other companies&#146; certificates of incorporation has been challenged in legal proceedings, and it is possible that, in connection with one or
more actions or proceedings described above, a court could find the choice of forum provisions contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our common stock and Series A Preferred Stock is Computershare Trust Company, N.A. The transfer
agent&#146;s address is P.O. Box 43006, Providence, RI 02940-3006. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing on The Nasdaq Global Select Market </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The Nasdaq Global Select Market under the symbol &#147;OVID.&#148; There is no established public trading market
for the Series A Preferred Stock, and we do not expect a market to develop. We do not plan on making an application to list the Series A Preferred Stock on Nasdaq, any securities exchange or any recognized trading system. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tocb561116_8"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into a sales agreement with TD Cowen, under which we may issue and sell from time to time up to $75,000,000 of our common
stock from time to time through TD Cowen acting as our sales agent or principal. Sales of our common stock, if any, will be made at market prices by any method that is deemed to be an &#147;at the market offering&#148; as defined in Rule 415(a)(4)
under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TD Cowen will offer our common stock subject to the terms and conditions of the sales agreement on a daily
basis or as otherwise agreed upon by us and TD Cowen. We will designate the maximum amount of common stock to be sold through TD Cowen on a daily basis or otherwise determine such maximum amount together with TD Cowen. Subject to the terms and
conditions of the sales agreement, TD Cowen will use its commercially reasonable efforts to sell on our behalf all of the shares of common stock requested to be sold by us. We may instruct TD Cowen not to sell common stock if the sales cannot be
effected at or above the price designated by us in any such instruction. TD Cowen or we may suspend the offering of our common stock being made through TD Cowen under the sales agreement upon proper notice to the other party. TD Cowen and we each
have the right, by giving written notice as specified in the sales agreement, to terminate the sales agreement in each party&#146;s sole discretion at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate compensation payable to TD Cowen as sales agent will be up to 3.0% of the gross sales price of the shares sold through it
pursuant to the sales agreement. In addition, we have agreed to reimburse TD Cowen for fees and disbursements related to its legal counsel in an amount not to exceed $50,000, and for certain other expenses, including TD Cowen&#146;s FINRA counsel
fees in an amount up to $10,000 pursuant to the sales agreement. We estimate that the total expenses of the offering payable by us, excluding commissions payable to TD Cowen under the sales agreement, will be approximately $315,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The remaining sales proceeds, after deducting any expenses payable by us and any transaction fees imposed by any governmental, regulatory, or
self-regulatory organization in connection with the sales, will equal our net proceeds for the sale of such common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TD Cowen will
provide written confirmation to us following the close of trading on Nasdaq on each day in which common stock is sold through it as sales agent under the sales agreement. Each confirmation will include the number of shares of common stock sold
through it as sales agent on that day, the volume weighted average price of the shares sold, the percentage of the daily trading volume and the net proceeds to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will report at least quarterly the number of shares of common stock sold through TD Cowen under the sales agreement, the net proceeds to us
and the compensation paid by us to TD Cowen in connection with the sales of common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Settlement for sales of common stock will
occur, unless the parties agree otherwise or otherwise required by law, on the second business day that is also a trading day following the date on which any sales were made in return for payment of the net proceeds to us. There is no arrangement
for funds to be received in an escrow, trust or similar arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the sales of our common stock on our behalf, TD
Cowen will be deemed to be an &#147;underwriter&#148; within the meaning of the Securities Act, and the compensation paid to TD Cowen will be deemed to be underwriting commissions or discounts. We have agreed in the sales agreement to provide
indemnification and contribution to TD Cowen against certain liabilities, including liabilities under the Securities Act. As sales agent, TD Cowen will not engage in any transactions that stabilizes our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on Nasdaq and trades under the symbol &#147;OVID.&#148; The transfer agent of our common stock is Computershare
Trust Company, N.A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TD Cowen and/or its affiliates have provided, and may in the future provide, various investment banking and other
financial services for us for which services they have received and, may in the future receive, customary fees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tocb561116_9"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cooley LLP, Washington, DC, will pass upon the validity of the issuance of the shares being sold in this offering. Certain legal matters
related to this offering will be passed upon for the sales agent by Paul Hastings LLP, New York, New York. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tocb561116_10"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Ovid Therapeutics Inc. as of December&nbsp;31, 2022 and 2021, and for each of the years in the <FONT
STYLE="white-space:nowrap">two-year</FONT> period ended December&nbsp;31, 2022, and management&#146;s assessment of the effectiveness of internal control over financial reporting as of December 31, 2022, have been incorporated by reference herein in
reliance upon the report of KPMG LLP, independent registered public accounting firm, incorporated by reference herein, and upon the authority of said firm as experts in accounting and auditing. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tocb561116_11"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of the registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> we filed with the SEC under the
Securities Act and does not contain all of the information set forth in the registration statement. Whenever a reference is made in this prospectus to any of our contracts, agreements or other documents, the reference may not be complete and you
should refer to the exhibits that are a part of the registration statement or the exhibits to the reports or other documents incorporated by reference into this prospectus for a copy of such contract, agreement or other document. Because we are
subject to the information and reporting requirements of the Exchange Act, we file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the
SEC&#146;s website at http://www.sec.gov. We maintain a website at www.ovidrx.com. Information contained in or accessible through our website does not constitute a part of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tocb561116_12"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; information into this prospectus, which means that we can disclose important
information to you by referring you to another document filed separately with the SEC. . The information incorporated by reference is considered to be a part of this prospectus, and the information that we file later with the SEC will automatically
update and, where applicable, supersede the information already incorporated by reference.&nbsp;Any statement contained in this prospectus or a previously filed document incorporated by reference will be deemed to be modified or superseded for
purposes of this prospectus to the extent that a statement contained in this prospectus or a subsequently filed document incorporated by reference modifies or replaces that statement.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following documents are incorporated by reference into this document: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1636651/000162828023007648/ovid-20221231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the year ended December&nbsp;31, 2022, filed with the SEC on March&nbsp;13, 2023; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the information specifically incorporated by reference into our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2022 from our <A HREF="http://www.sec.gov/Archives/edgar/data/1636651/000095017023014914/ovid_def_14a.htm">Definitive Proxy Statement</A> on Schedule 14A, filed with the SEC
on April&nbsp;27, 2023; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Reports on Form 10-Q for the periods ended March 31, 2023, June 30, 2023 and September 30, 2023,
filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1636651/000162828023016013/ovid-20230331.htm">May 5, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1636651/000162828023027430/ovid-20230630.htm">August
 4, 2023</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1636651/000162828023036564/ovid-20230930.htm">November 3, 2023</A>, respectively; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1636651/000095017023015343/ovid-20230427.htm">April&nbsp;27,
 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1636651/000095017023016250/ovid-20230501.htm">May&nbsp;
1, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1636651/000095017023027151/ovid-20230608.htm">June&nbsp;
9, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1636651/000095017023050995/ovid-20231002.htm">October&nbsp;
2, 2023</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1636651/000095017023053875/ovid-20231017.htm">October&nbsp;18, 2023</A>, to the extent the information in such reports is filed and not furnished;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock contained in our Registration Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1636651/000119312517157155/d381531d8a12b.htm">Form
 <FONT STYLE="white-space:nowrap">8-A</FONT></A>, filed with the SEC on May&nbsp;4, 2017, including any amendments or reports filed for the purposes of updating this description. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also incorporate by reference into this prospectus all documents (other than current reports furnished under Item 2.02 or Item 7.01 of Form
<FONT STYLE="white-space:nowrap">8-K</FONT> and exhibits filed on such form that are related to such items) that are filed by us with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (i)&nbsp;after the date of the initial
filing of the registration statement of which this prospectus forms a part and prior to effectiveness of the registration statement, or (ii)&nbsp;after the date of this prospectus but prior to the termination of the offering. These documents include
periodic reports, such as Annual Reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Quarterly Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> and Current Reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> as
well as proxy statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You can request a copy of these filings, at no cost, by writing or telephoning us at the following address or
telephone number: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Ovid Therapeutics Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attn: Corporate Secretary </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">441
Ninth Avenue, 14th Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">New York, NY 10001 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT STYLE="white-space:nowrap">(646)&nbsp;661-7661</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g561116g05d52.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>$75,000,000 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:96pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>TD Cowen </B></P> <P STYLE="font-size:96pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:96pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>November 15,
2023 </B></P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g561116g05d52.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g561116g05d52.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1M<4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &T"^:78X0DE-! 0      "D< 5H  QLE1QP"   "  << @4 %4]V:60M
M5&AE<F%P975T:6-S7W)G8@ X0DE-!"4      ! F%^,IWV>0I(^(D/,H&I8D
M.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
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M;       0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6)
M;^            !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M        0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M            4G-L=%5N=$8C4'AL0'D            *=F5C=&]R1&%T86)O
M;VP!     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2
M;'0               !4;W @56YT1B-2;'0               !38VP@56YT
M1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O
M<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M  UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M   X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M         #^    X0DE-! T       0    >.$))3009       $    'CA"
M24T#\P      "0           0 X0DE-)Q        H  0         ".$))
M30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       !
M #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M  !P  #_____________________________ ^@     ________________
M_____________P/H     /____________________________\#Z     #_
M____________________________ ^@  #A"24T$"       $     $   )
M   "0      X0DE-!!X       0     .$))300:      ,U    !@
M       !D@  !.P          0                         !
M      3L   !D@                     !
M !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG   !D@    !29VAT;&]N9P  !.P    &<VQI8V5S5FQ,<P    %/
M8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '
M9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90
M  !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P
M(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   9(
M4F=H=&QO;F<   3L     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M        37-G951%6%0    !       &86QT5&%G5$585     $       YC
M96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH
M;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M"79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0
M   +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO
M;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M    #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M    .$))300H       ,     C_P        .$))3001       ! 0 X0DE-
M!!0       0    #.$))300,     !#      0   *     S   !X   7Z
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M##O,'B$/\']+_!=[E?A^3)@,X3XN$F,1/6<^'^L^J*+WLK8ZRQP8Q@+GO<8
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M+_K%W5?J\S[38Z[+Q+'T76/,N='Z2E[O^L65I@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! ?_  !$( &$!+@,!$0 "$0$#$0'_Q  ?   !!0$! 0$! 0
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M(]SLS4N)-RMUVY)ZV]79HF*JP#QW967F1@5=21AD8%74E6!4D:GE **#U!0
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M<<5SU:M6+MF>W;F>>S9E>:>:0\SR22,69F/S)Z 8 &    -2'1%Z# 4= /0
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M/%6:/%^:E$KLY*$1;VA\2>$FWR+[=PUSU+4+K*VW2RM+6L*C!F2"65FEKS$
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MOCCC0HJL%:!H>[+8@!ANS['W96HK8$[8Y3V\8+.%BK"Q(UVJ!..94@2*K4:
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MY,OY0R4VVKPSXYL 4V:+;^%.()F_F;.1'4V/<W8_S1F*U]LN$_\ -"8Z<_\
MS3R9:E"RCLY_)7[/V?EG_MQ_O_MYM%?_ %3TZ$],>GR/]^OHH(!UZ?P'\<ZA
MISK0R=H0YQ["5+C[36S!O5C[I>6^0 I2<9_+.6#GTYSC\TY5C/\ )UU1^1W+
M+5\9Z21\RI=X>W^K. W1HE@ANA6 /4>?4A;!&.95.<C7*OY9="*7P2OS2(I>
MEQ%P_9A)"DK*]F6DQ7IT)AMS*2/U68=CK8AV3)HV>[6_$0P];CCXU*M,*VIU
M65*P%7MEW:"CD8SG_P!&S'QPK+2<?9+3:$I^V,==4>(T2Q<:[\JXPUB"4X_I
M34JTKY^?,Y)^)ZZ^3M8DP1D]^7'X$C5J'6DZ7US/>]/IF4TIW+.3\6:$\/&7
M^Z)W%6BW&O:8E(C:00]K-*"\?9P<&SFV*!<<Q]OG88M&?NC/787AWN";CP?L
MSJP+U:_YOF7.2CTF,"JWP+0+#(!_1D4^NH:RI69_@QYA]&&3^_/_ (]SIZ^&
M;Y'UV_\ #6T<=7Y 5J\:!V#/2#4,IY"2RM?;+-=M$5.,,K7AQYIJX/W",/4P
MA3064162%(7)#X<IKQBVB6KQ#!NP0FMNE6)3)CW5M4U$#QD@8!-<5W7)RWOX
MZ(</:3AHRF1E">GKRMU!_P#:YM:2.JBT\T=&C6*SXH[DA7[1L[C[Q>KTD,=)
MZMA[)LO8K SJ'LQDU?F8:/I<.;Z<9^4DAJ[#RDX\(M7NKC+3"EJ0EI]A;G1'
M@MM$L-/==ZE1E2[)#3J$C'/'5,CV9%_I(TTB1!L8#P2KDD$".O."4C![99OJ
M>B_?C)^A!TS?PP>FI2V\RMJ[G<!=76=/:5D(;,EA&?98NFS9^) @0U+RGT^H
MFKUZ]O92E6'$Y&;\X]"\^9#QFW!(.'Z.W!AYU_<5DY">IKTXG:5@/E--6&>V
M&/KK&DN9&;T5<?>Q']P.M /?\XNXY%]OB]VF&CDFWGCE)"[KKRVF,N&.5V&9
M>C=D1Z'48RX@/\%2$C9"&<)6@@NK1N%I2IM#K56^%V]?FGBJM#(_+6W9&VZ8
M$X42R$/3?!Z<WM*)"#TPL[_$@NK:<\+$=TPX^@^U_P!TD_4#6,_M#<D/W+O<
M(XZW\X_ %3LEN:U1?''7LL!)J6T4XJ)!\DO"DX^1KDQ(0UM=]7J2E=?:7E"O
M1A.>@N/-H_/7"N[557FGA@-ZJ ,MY]+].$08/O31K) /E*1D:CJ[\DR'T)Y3
M]&Z?N.#]VKU/BF.2.'2^./$N&D$J2*B6WU?0FW<*RDA[$C1=;(>PC_Q;C;&-
MC$NCNY]66RHTG#>$J:<56O@KM&%W??9$.24VNJQ'H.2S<P3W!/L@!'3*N,YR
M ZO/]B,'XLW\%_O_ ':9GX8'BYFX[VV_RQGX[*X73=9:US0RGV$J9=O^PV'7
M+"< ^K&<I,KE'">C34)RA6!;^/GU92I2>I#QFWKV?;*&QQ/B3<)C;M*#U%6H
M0(E8?T9K+!U/QJM\M8TDRS2$=%'*/J>IQ\P,#Z-K4UW+OXO+F[_19WE_9U8.
MJ4X/_P!*^'/[;VS_ 'R'3Z;^2E_JW_V3KF*Z;_QO:J_G(HW^L\7UV1N7^;K_
M /U*U_[A]0J?;7]I?XC6U_XI&-DB.&>B),=IY<7&\E8YF2<1ZLM,OR&LMB8C
ME/>/T<>OY4MMM2OR4K*<9\K^_._@LZ#B'<T) =]G<H/4JEVISX^G,I/_ (:D
M;W\DI^#_ /\ 5M9\>P'8:[7NZ7Q_587AALS,3M:O01!64I;;L4MJVV-1K*%K
M^R29!*"(L7&,X4\2<T.CRI[&,VGXI132\%;IY09O+DHRRJHR3#'=@+D_ZJ$B
M1CZ!"3T&FM0@3KGU# ?7!_'71WZY)U+Z;;<TW 5K3^UK':WAAJM :VO,U9"#
M5(2&Q 1=8E#IAXI3GZM(S<>P0M_*_P!##>%>K[>>GFWQRS7Z,, )GEN5HX0N
M>8RO,BQA<=<ER,8ZY[:\; !)[ '/TQU_=KD<==V:@-=8KB+_  4.,/\ 1YTM
M_9M6NN'-]_SYO/\ :NX_[W-J>3["_LK_  &I#=16LM'1HT=&C1T:-'1HT=&C
M3&\C>..GN5VH[1I'>50#N-"M0Z4D"/9R/)0\F/ZU1ECK<LUCYN"L<,^K)$9*
MA+2ZWG+HQ"20"C R)+:=VO['?@W+;9VKVH&RK#JDB''/#,GV989 .5XVZ$8(
MPP5ABZ+(I5AD'_&1\"/CK))?>T7W2>VAL><VKVT]NV79NO9 C!#]=K\A" WA
MR-'=6\)&;#U3:L+H.R\1S2\"A2T(Q)2A3BBBQ:O7/>PUF]:O'G!?&%2.CQA0
MAI6E&!+*LKU@Y&&>I>@Q:I\Y]YHY"B*.56FFQG3 UYX6+0,2O?&1GZ,I'*V/
MB.O?H/7ZVN]UWIZ&TNGWW@G&G7 ;&!D&S_&KD) 2S[N/T</EQ$;: (\QQW.,
MJ2J,%CQ',9PIAOT9QG.)\./#NR?/K<3.L#=>6+>-IEC /H)'@9P!TZ.S,#T)
MSV!9LKT:'K\>1QGKT]<?AT^&D58J+W_.[3EFE;-@K#QUT/,N-XGHNRP!_'K6
MRP,J0ZI4Q6C4&;?V,$[CVW@HR09M,)DID=_'T_*5&H<PVO"[@7-FG+%NVYQ@
M^4\,J[K<#CI^CF7EH4W[AG4P2<I(]X$*?"+<_0CD0]P1R#MZC[9'R.1GX'5B
M\+3N 7PYVF0;?;W9/>?+/:D67' R H,8%?;B,%[#DC'58(LDP+5&I09'(>)F
M4?*E)::.R-@ARU&1T=#Q6I26.*?%K<&@@";;L5)P[*S.U6NS9"/.RA6O7V3F
M\M $2->;E$"N[R+ 14UR<N[9ZX',?D!V51Z]2?CDXU L_P")MYASIQ,_1.&^
MLVJ"A]>6VSE[0MQS S:_#C1-OAWZY#.$(2E25OIK@[:%^<J&SC'IZD9_#K@/
M;;$>V;MQU5J;NZJ14GW'9J-ARX!4Q[?9E>T5;(*@.W,",$Y!T@U\@Y*HH].9
MCG\>@_=I]*]\593/PD\Y;N'5H9OK#+B&@*]MF*>J1Y2$>$./2LG31IF&9==\
M^X.F&G'!4?;!!:NLY?!*P9Q[/Q! U1B#SRT7$ZH>O1([#1RD#LWF1!N^%&E!
M>4C)C.?3# @_?@8_ ZA_2M5<[/B#^2M/VINZ"DM.\-Z :X@(H 22CJ9!U=XP
M8B:K6KGYAM+VP=FVYH,4.?N_L/1<.E@<N0;C@8^ J1D_9O<,^%>SV*.VRI?X
M@M*"RLR/8EF"L(YKHC.*M. LS15LAY,E5YV>6=4PLMMPS>[$.W?&#WY?Z1..
MK>GR[:V^4VH5K7U1J]#ID0)7ZC2Z]#52KP0"5("AZ_7XX>*AXP5*E+7A@&/$
M'&:]:UN90WC*UK7E2L\XV+$UJ>:U8D:6>Q+)/-*W5I)97+R.WS9V+'&!D]-2
M0    P   /@!T TH\XPK&4JQA258SA2<XQG&<9QXSC.,_;.,X^V<9^V<=(]^
M^L@2"""00<@CH01V(/H1K'!S3HD-J?E)NBBU]IH.#C+6F3B@6/2D:. M41&6
MX6,&1C./;&C&IY( [>?NVR.VC.5>GU9XJXVV:#:N*][HU5$=:.YYL,:#W8X[
M<45M8E^"0B<1(.I"H 23UU]P_ CB"[QGX1\"<0[D[S[A;V8U+EB0YEM6=GNV
M]EFMRL?M36WVXV96'1I)68 <V!3WSQM; >L(&LI=3\[8[2P1AGU>5*CH,0E\
MMW&/O]D&EQ2/S\9]S.<><IZZ7_(TX<FN>(V\;^4/LFP<.3Q&0+T%[>+->"K$
M3V'/4K;E)WY@8@,8)Q0'Y=._UMK\+]CX=#*+W$O%%>5(LCF.W;)4L6;DN!W\
MNY9VN/Z3DY&,'=EVO=8':=[>O$*A2HSP4L'I&H6"7!);4T3'R]Z&7>Y2/);5
MC"FR #[*0&^A6,90ZPM.?RZN7C.ZNX<5;]:1@T;;E8BC8'(>.LWLR.I'=66$
M,#\"-?+6%>6*,?Z@)^I&3^\ZGEUK&E=9_P#OR=L6;YKZA@]VZ4A,2O(K1<5(
MCL5X1O&9+:.LB'G).2IP.<>%$62N2*RK!31,JQ@U<A9(5EMV0FX]3-I>&7&4
M7#E^7;=QDY-IW-T8RL?<I7 .1+#?"&9 L-AOU0D,A(2-\M+4!E4,HRZ@C';F
M4]Q]?A]_QUB"XR<GMZ\)=WP^X=,3Q5-V!4R"XB8B)8-]R(GXI1"&YVDWBNO+
M%5(PISHJ6I".?4*?'G"C2,:5&3D:!(!]'[SLVV<1[;)M^XQ+8J3A9(Y(V DB
M<#,5FM, W)(H;*. R.K,CJ\3NC1J.\3\R]",@@^OQ!'J/X$ CJ,C71I+XI'C
ME,5L-OD+H+;M$N;3#3<@]JM55V%4#R4(]+Y8BK)8Z)/1+1*\>ZS&.AS:A$K]
MAR8,RU\R]1&X^"V[1RL=JW2A9KDGE%T3U)U4]E;R8;44A4="X:/F[B-<X$@M
MY"/?1@?]7##]Y!^[!^OKIJN4GQ1E175I.!X=Z,MWXND!7A0]A[S^@1D96GG$
MY1B1 H53G+0JRD-)5E8B)6T0@;!*6W38^4&2X$\]V7P7G$Z2[_N<'D(P9JFV
M>:[S ?J-:GCA\D'];D@E8@D*Z-AAC)>&,1HQ)Z<S8 '3N ,D]>G7E^/;64-I
MG>?+K>JD,M6[=.^=V7)QY>&T.2UGM]KG"%.O/+PC#; PS2?4XZO. H6!B!5+
M7F.AX_.1[P)VW8=LZF#;MKVZN!U/)#7@B& /4L3V ]Z261OUY'ZL/?D?U9F/
MU))_N_< ,GIVZ/O:KX"Q7;VXKP&K3'8Z6VO;3/QUNFS1V,."R%UD!&!T0446
MMMM]^N4V,9'@8AQS#:#GV9.?2*$].$"M\D<;<4/Q5O<MU0\=&!?9MNA?HR5D
M8DRNH) EL.6ED R5!2+F81@F8@B$*!>Y/5C\_@/D!T'WGUU8I/0<39X.9K4^
M /*P5ABI&#FHPMO#HDC$RP;P$B 4UG[.#F!D/#O-Y^RVW%)S]L]:E%(\,D<T
M3%)8G22-UZ,CQL&1@?0JP!'S&EN_?7*<YB<?)KB;RFWAQ]E,F)>U9L2:A8(\
MK&62Y2I.OIEZ)8L^GQEM<_3Y"!G4>C.?;^?QA*LY3YZ[=X?W6/?-DVW=4Y<7
M:D<DJKU5+ 'EVHOGY5A)8OGR:@I$Y)'3K[K$#N,CN#]X(/\ ?K^<N.4NP^8^
MZY3>.SGDJM,K5M?UA]EIY;PK#-'I4'5''Q$K2CY=,Y(11]E,80G"$2DV?E.5
MY5E:C8MDJ</[<FVTAB%)[4X) #$V;,LX#8[^4CI I[^7$G;& 2R-*_,>APH^
M/0 #]^"?O.NAUV=>+O[D_M^:,I$E'8CKO>896Y-CH4CVROQ;LID689!/1Z<9
M2?6ZFBKU$M/E>,/5]>4K4G.,]<I<?[U^?.*=SLH_-6K2?F^IUROD4RT99.I]
MV:?SK"]NDO8:EZZ>7$@/<CF/U;KC[A@?=IX>Y=_%Y<W?V?\ )9WE]_\ W=6#
MJ/X/_P!*^'/[;VS_ 'R'64W\C+Z?HY/]DZYBNF_\;VJOYR*-_K/%]=D[C_F^
M]_U.U_[A]0J?;7]I?XC72][IG$8OFQPCW'I. 99=V!]."O6K<ON)90K8=')Q
M-0L;[[GZD?%H$;DZ<Z4_^I#8L3Q:\H]C"T\?<%;\O#G$>W[C*2*O.U:[@9/L
MED>7(^.Y\EBE@*.K&(+ZXU,S1^;&R>I&5_:'4?CV/R.N9I SFP-*[)B;%"%3
ME VAJRYB2D<2IAZ,L=/NU-F$/LY=%+:2\%*PDU'X20(8QY:)'<'*85C#C>>Q
M)8JNX5)(95CM4[M=D=<AXK%:Q&00&4X9)(WZ,IZ@@J>QU"@LC C*LI'<=01]
M?7ZY^8UL_P"+_P 3QQ\FM?1$?RRUKL2D;3C 61IN=UA!Q=NH-J*'92AV8CPS
M+!$6&L$R+J5.K@'@YH$%:_2U87VLX0SSUO7@UNL=J1]BMU+-%V)CBNRO!;@4
MGI&[+$\,RH.GFAHW;UA!ZF1CNH5'F ANQ*]5./7N"/F,''Q.J[NZKW]U<NM8
MS?&OBO2[A0-675#0&Q[W>,1H5\O$*E]IU=-A:_ R,T'6JY)$,M8FC79T^7L<
M>K,*X##1[LF/*[9P1X7_ )ANQ[QO=BO:NU\M4JUN=JU:3! L22RI&TTR GRU
M$2I$_P"D#2,$*)6+?F+R1@A3]HD=2.G0=2 #ZYZD9 QWUF7_ -_]_P#^_P!?
M5Q:9?X_Q_P#7\==8KB+_  4.,/\ 1YTM_9M6NN'-]_SYO/\ :NX_[W-J>3["
M_LK_  &I#=16LM'1HT=&C1T:-'1HT=&C1T:-'1HT=&C1T:-8)NZLD?87?4/J
M/(-?_%I'.ZBKE1 F'5-0;]3<U;$V* BFW'5I:5#6#9DO+-RR$KPPY(2DN&]E
MOPZENQ^.]UXKX:_):XYWSPV$_P#RPJ['N=N">C&9;]4_G2.ON^X5456?VW;.
M'A:NU'53)$]6":,,R*&A[I;SFSZ*H7Z$9_VB=642:@(>/'BHH02.C@!VQ @
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M#OCW">V1G(]6BV1S.H'KR@D_=G&/KU^FM+G!GM@<3>W_ !+RM+TTF6V'* X
MLFXKX0-8-C30JLI6\ /(-!@QE8A7G$H4["U2+A@S?8%<E\2A8K1>*>XEXSWW
MBF0?G&PJ5$8O#M]53%4C;KABA9GFD .!).\C+EA'R*Q73V*&.(>Z.OJQZL?O
M]!\A@??UU8=UJFE='1HUG,[M'8\MG/[D'7-^ZBV9K[6,R[0(ZH;##N,;82<V
M*2KIQF*]8!78(,S"BDP)K,$;\UAK.!(2(2SE>,.>BVN!O$B#A;:IMKOT[5R,
M6GL5&KO$OE),J^;$PE9?=\U3*O+GWI),^FFD]8RN'5@IQ@Y'?&<'I\NGW#4
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MD#!YI68_:&GPYW]QOC9V]J*%:-VV PZU6-HK\!:JJ30TE?[L\)G"'R @""1
MXB #=4E$C9ITR/B1UY^3%>/EW1(LKH7AGA'>.*K+0[=$JP0E?:KTY*5:P;J
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M+UVRY_7L7+4DL\K8Z9=R?0'&M5NGM,:JX_Z^@-5:7HE=UQKZLL*8AZQ60$!
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M'L.X<07&IT%B!CB>Q9LV)!!4IUH\>98M3L"(XER <!F).%4]<9R2+&,MGJ0
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MGAW1FW^^\+G8:T+6-XVFUN+3K!9VFC9%BY19HY)#[1RCD!C*+%*%SRRR*H+
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M=NM[9N&WW8*N^))+-%9KL%01R0PHX\Y8R<R*0,D9/0^2R&10%AFYE9&4M&0
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M7'&T[E0XCWRS;I68*UO>+\M:U)!(M>PEB>6Q&89BOE2$Q.&949BA!5@""!Y
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M506(RV=>8&2<#)[G'4_4Z_S8:73K<_7RK94ZS9R:E.AVBJD6&!BYI^LV6/\
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M"#W!&0?N.FIU3Q7XS:)DC)G2O'O2NIIF0;<9.F-<ZPIE-EBV'<XRZ,_)0$,
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M$B#Y=<<<RP.ZVRI;CBE(SE:LY=T=XW;; PVW<[] .<NM.Y8K*YP!EEAD0,<
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BLM'1HT=&C1T:-'1HT=&C1T:-'1HT=&C1T:-'1HT=&C7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g561116g10k06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g561116g10k06.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1J:4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &GZ^9X(X0DE-! 0       \< 5H  QLE1QP"   "  < .$))300E
M   0!G+@RAB"MY^QV7 3G\<:@SA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!PIB#
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU
M  (  CA"24T$)@      #@             _@   .$))300-       $
M'CA"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              N,   :.          $
M                 0             &C@   N,
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   N,     4F=H=&QO;F<   :.
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   +C     %)G:'1L;VYG   &C@    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $     SA"24T$#      0&
M  $   "@    1@   >   (-    /_  8  '_V/_M  Q!9&]B95]#30 "_^X
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MKC!@G]U+_FS];R/Z;_[-W#_OJ7WW
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $* ET# 1$  A$! Q$!_\0 'P
M 00# 0$! 0            ,$!@<"!0@!"0H+_\0 ?Q    8  P0#!PH,# T,
M$ 4% 0(#! 4&  <1""$Q00D241,4%6%Q@<$6%QA6D9>AL='P&1HB)28R-C=7
M==7A(R0U0D5259.5EM;Q)S1#1EAE9G)VL[33U"@S1U-C<W2%AI3#Q0HX.41(
M5&)G@X2'I::RMM)D=Y*UQJ.DM\+$_\0 '0$  @,! 0$! 0            (!
M P0%!@<("?_$ &H1  (! @,$!0<%"@D'!@L$"P$" P01 !(A!3%!4083(F%Q
M!Q0R@9&Q\"-2H<'1%1<S-$)4DI32X0@6)%5B<M/4\1@E0U-6@I,U1)6BLL(V
M15=C9'-T=82%PR9E@Z.DLT9'AI:EQ&:TQ?_:  P# 0 "$0,1 #\ _?Q@P8^7
M72W[>EDZ/C9=;9JT2L0MHS$N]^A\L:0A92O5:U#2<G!V2RO;%.LX]W'O9)I&
MQ-7>HMHQK),%'4H^CS+. 9(NP'UO0GHQ'TJVWYC43204L%))65+16ZYXHY88
MNJB8@A'=YUO(0<JAK M8&J63JD+6N;V X7U(OW::_5OQ^3,W_9#_ $EHF$0O
M&5Q $1$"%RFK1BE 1$>J43]8XE+KH43F,?0 ZQC#J(_<_O5=$ +>;UYMSVA)
M?=Q^3WW^WNQB\YF.N91?6V0:?3CSZ8>Z2[V\Y7^]+6/DQ/WJNB'YO7_K[_L8
M/.)OG+^@/MP?3#W27>WG*_WI:Q\F#[U/0_\ U%?^OR?L8/.)OG+^@/MP?3#W
M27>WK*_WI:Q\F#[U71#\WK_U]_V,'G$WSE_0'VX/IA[I+O;SE?[TM8^3$?>J
MZ(?F]=;_ -X2>[J_KP><3?.7] ?;@^F'NDN]O.5_O2UCY,'WJNB'YO7_ /2$
MG['QS&#SB;YR_H#[<'TP]TEWMZRO]Z6L?)B?O5=$/S>O_7Y/V,'G$WSE_0'V
MX/IA[I+O;SE?[TM8^3!]ZKHA^;U_Z^_[&#SB;YR_H#[<'TP]TEWMYRO]Z6L?
M)@^]5T0_-Z_]?D_8P><3?.7] ?;@^F'NDN]O.5_O2UCY,!\E/1#\WK_U^0>Y
M,'G$WSE_0'VX/IA[I+O;SE?[TM8^3$?>JZ(7/\GK_P#I"3W9+#U8/.)OG+^@
M/MP?3#W27>WG*_WI:Q\F)^]5T0_-Z_\ 7Y/V,'G$WSE_0'VX/IA[I+O;SE?[
MTM8^3!]ZKHA^;U_Z^_[&#SB;YR_H#[<'TP]TEWMZRO\ >EK'R8/O5=$/S>O_
M %^3=_P_H^G!YQ-\Y?T!]N#Z8>Z2[V]97^]+6/\ [<1]ZGHA_J*__I"3]C3X
M._!YQ-\Y?T!]N#Z8>Z2[V\Y7^]+6/DP?>JZ(;O-Z^W_O"2__ &/KUP><3?.7
M] ?;@^F'NDN]O65_O2UCY,3]ZKHA^;U_Z^_[&#SB;YR_H#[<'TP]TEWMYRO]
MZ6L?)@^]5T0_-Z_]?D_8P><3?.7] ?;@^F'NDN]O65_O2UCY,'WJNB'YO7_K
M[_L8/.)OG+^@/MP?3#W27>WG*_WI:Q\F#[U71#\WK_U^3]CX]>#SB;YR_H#[
M<'TP]TEWMYRO]Z6L?)@^]5T0_-Z_]??]C!YQ-\Y?T!]N#Z8>Z2[V\Y7^]+6/
MDP?>JZ(?F]?^OR?V?QZ\'G$WSE_0'VX/IA[I+O;SE?[TM8^3!]ZKHA^;U_Z_
M)^Q@\XF^<OZ ^W!],/=)=[>LK_>EK'R8/O5=$/S>OM_[?)[NK^O!YQ-\Y?T!
M]N#Z8>Z2[V]97^]+6/DP?>JZ(?F]?^OR>O\ T?\ CW8/.)OG+^@/MP?3#W27
M>WG*_P!Z6L?)@^]5T0_-Z_O_ )?)]'8^S!YQ-\Y?T!]N#Z8>Z2[V\Y7^]+6/
MDP?>JZ(?F]?^OO\ L8/.)OG+^@/MP?3#W27>WG*_WI:Q\F#[U71#\WK_ -??
M]C!YQ-\Y?T!]N#Z8>Z2[V]97^]+6/DP?>JZ(<:>O_7Y/[,?%_6><3?.7] ?;
M@^F'NDN]O.5_O2UCY,'WJNA_^HK_ -?D_8P><3?.7] ?;@^F'NDN]O.5_O2U
MCY,'WJNB'YO7\?\ G\G['^'#?@\XF^<OZ ^W!],/=)=[><K_ 'I:Q\F#[U71
M#\WK[?\ M\E__P!7]>#SB;YR_H#[<'TP]TEWMZRO]Z6L?)@^]5T0_-Z_]?D_
M8P><3?.7] ?;@^F'NDN]O.5_O2UCY,'WJNB'YO7_ *_)^Q@\XF^<OZ ^W!],
M/=)=[><K_>EK'R8/O5=$/S>O_7Y/V,'G$WSE_0'VX/IA[I+O;SE?[TM8^3!]
MZKHA^;U_Z^_[&#SB;YR_H#[<'TP]TEWMYRO]Z6L?)@^]5T0_-Z^W_M\E_P#L
M?3?!YQ-\Y?T!]N#Z8>Z2[V]97^]+6/DP?>JZ(?F]?W_R^3Z.Q]F#SB;YR_H#
M[<'TP]TEWMYRO]Z6L?)@^]5T0_-Z_P#7W_8P><3?.7] ?;@^F'NDN]O.5_O2
MUCY,0/)5T0_-Z_\ Z0D/O3!YQ-\Y?T!]N#Z8>Z2[V\Y7^]+6/DQ/WJNB'YO7
M_K\G+^I]'KP><3?.7] ?;@^F'NDN]O.5_O2UCY,'WJNB'YO7_K\G[&#SB;YR
M_H#[<'TP]TEWMYRO]Z6L?)@^]5T0_-Z_]?D_8\?H]1YQ-\Y?T!]N#Z8>Z2[V
M\Y7^]+6/DQ'WJNB W4]?Z]H2>_(<'G$WSE_0'VX/IA[I+O;SE?[TM8^3$_>J
MZ(?F]?\ K\G['QNX8/.)OG+^@/MP?3#W27>WG*_WI:Q\F#[U71#\WK_U]_V,
M'G$WSE_0'VX/IA[I+O;SE?[TM8^3$?>JZ(<*>N_Z0D'_ -,X/.)OG+^@/MP?
M3#W27>WG*_WI:Q\F)^]5T0_-Z_\ 7Y.^W^C]OUVP><3?.7] ?;@^F'NDN]O.
M5_O2UCY,'WJNB'YO7_K\@_\ IGX\<'G$WSE_0'VX/IA[I+O;SE?[TM8^3!]Z
MKHA^;U_Z_)^Q@\XF^<OZ ^W!],/=)=[><K_>EK'R8/O5=$/S>O\ U]_V,'G$
MWSE_0'VX/IA[I+O;SE?[TM8^3!]ZKHA^;U_Z_)_9^/P=#SB;YR_H#[<'TP]T
MEWMYRO\ >EK'R8C[U71#\WK^'_C"3G_4_P =QTP><3?.7] ?;@^F'NDN]O.5
M_O2UCY,'WJNB'YO7_P#2$G=PR?X>LX/.)OG+^@/MP?3#W27>WG*_WI:Q\F)^
M]5T0_-Z_]?D_L_CU8/.)OG+^@/MP?3#W27>WK*_WI:Q\F#[U71#\WK_U^3]C
M[,'G$WSE_0'VX/IA[I+O;SE?[TM8^3!]ZKHA^;U_#_G\G]G_ (^O!YQ-\Y?T
M!]N#Z8>Z2[V]97^]+6/_ +<'WJNB'YO7_K[_ +&#SB;YR_H#[<'TP]TEWMZR
MO]Z6L?\ VX/O5=$/S>O_ %^3]C!YQ-\Y?T!]N#Z8>Z2[V\Y7^]+6/DP?>JZ(
M?F]?^OR?L8/.)OG+^@/MP?3#W27>WG*_WI:Q\F#[U71#\WK_ -?D_8P><3?.
M7] ?;@^F'NDN]O65_#B.4M8W\ T^UXCKN\^#[U71#_45_P"OR?L8/.9OG+^@
M/MP?3#W27</5UE?KO^I]:6L=;< #]J!==X" AXAP'R4]$ ;>;U]R=WG\I8:!
MO1ZN]B""+:6.#SB?YRVM>^06XW%[Z$6-[VW8/IA[I+M_V<Y7Z!^N]:2LB'DW
M%$0W[MX!OXXG[U/1#?U%>1\X5TI7?;A'>P) )( %Q? *B<Z9EONMD%[ZV&_>
M;>Z]KX/IA[I+M1#U=97@(!J/]"2LZ  <1$0*(!ISU$!TU$ $"FTC[U/1"_X"
MOO:^E?+:PWF_5@:7U!L3O (4D J)[7+*!>Q)4:>-B3NUTO;CJ1?SZ8?Z2W37
MU=Y7:::_>EK._=J.GU.\0W:AQ#4-VF#[U71 BX@K_P!?D&EB;_@^&EQO (-K
M8/.)A;M+8[CDTWVYWW]W"V_!],/]);H(^KO*\=XE !RDK1=1W: '6(7[81 "
MZ_;#N =X8C[U?1#7^3U_=_+Y #K;\J,$$G=<"^EL3U\_SEY^B-1S&OCOL18W
M Q[],/=)<.GV=97:CN /6FJXB(Z:Z  :ZB' =-0 1#?B?O4]$-/Y/77)*@?=
M!B2PW@60EK<2 0+CF+KYS,+W9=#8]CGNXZ7Y&Q[L'TP_TEPZ:7K*\=0UT]:.
MM;@UT^J'J=4!$0'<(];Q8C[U70^X^0K_ -?ETMI_J\O'=>^FHT&)\XG^<OZ
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MG6,;(*13A0I389.G&RH-G5>TZJDVI24])6_<YEJ*5%GEK5DECEIH(DFDZR6
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M_IKX_'G3C*.ENW[@G_.,QX\3X_&N.I%^"3^J,?0/KDUTZP:ZZ<>8!J(>YO\
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M:OE2"MIP*V7J6SH$K973JU'5S /'O:]PFMU8!"K#2M21*C6"YHX4ZVPL6EM
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M$Q7*DPS7CCE="V*B<I7:YDXU5!ZK0WEH\K:PU$XZ=SNE.\<;!(:=F<RK*RE
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M$46=W*[/FWG.*+)S>RG9YQF\C<O8B73FFLA)/[%&9>6)Q8F"%EGC6$DM..I
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MI.2"C%IB)R-W;E,"G$Q!!4PB01 HAS:GICTEG"K+M6=U1BZC) O:!(OV8P;
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M3=%U -WFK>F+_P"._2G^=Y_^'!_983_)Z\C?^PNROTZS^\XR#I"MM  T#/\
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M+J'#L^YO^?GKB?X\=*?YWG_X<']EA/\ )Z\C?^PNROTZS^\XR^B%;: ?[/\
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MD+*;Z66Q 50*4!5'%^L5H^J?,-6"HB$," "&6)5((L1?,+,PQI\PMG^/S*S
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M"JL1:Z&4'JG6^F:,Y"HW$QHK%49K1C+K9ES3Z[*PV2XFKJ:EQ\+I9=KKNYV
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M!R]U0733714ZH@!DEDTU4S )%"$,4Q0DN <I(N38;B";E=#F%Q?<1HV];WQ
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MH['F6=6:XT-[C2V+UPV+/CC]7UZ8,&#!@P8Z+K'W/Q'_  )'XAQYVH_#S?\
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MDU8(A1ESC,P9Y8[ 6U5TCE9TMV!F$9 >Q"B/LA3'<<F//'8 Q1T\[C-<K'/
M:F%U)]-B)@KE"07ED56=PRC=QF:V234191&8.6;32/2D!:Q]CKC8I8EI&.A;
M/3HMW:94H]"'@71FKDY2M@C(E4Z!^]&@BG9F4 .2<N4N"=%"[R0=W94%B;Y<
MMR3<8@ WW=K.R%+$'.I16L+ D!Y0+D7!E06)(!W2V:>6K83E<7RI(*)M&[XZ
M*L_&)KE:.EV#9LL*!W(*]5=Q*Q:*0=3KF5DXXG5ZSYJ"LM,JK*Q_T2EF WD!
M2V@T.H4E?G#4:$'#H3)DR"X>X##5;@A6%[6NC7#?-*L#J"!'H?/;*R88560"
MV,(M*Y9>U[-"$)-'+&BK3[2XC&<(^576-WB1P^D)B.CD&)':CE=\Y30;D6$Y
M!,SN$EFB.KP/&D@6Y_"]?D9; YP13S'LWL$UL64$-PJL197,BHUQ8F+JLQ)W
M*MYH@'/9.>X.AM:4?(QTM'L9:*?-).+DVC:0CI*/<(O&#]@]1(X:/63QNHHW
M=-72"B:S9PBH=%=%0BB9S$.41"]LUP;JN8BQWW(*DD  @BUV(!L2"1J8S#N_
M",ANP4C+(L9.5K,?2S%%!<!7!4%& Y)O^U?$1\U;Z[EO&GM)<N%V37-3, T=
M.S%)RZ=O7:3-O!BQK#-]-W>XJ+JBF:L0'>;=@)%#3=ABE40:J>%VCTSIO.Z^
MCV6HJQLM8QMG:1$DFS=E,T@18?Y.DDVT-H-UH/F%,8WC56ZR>&2RG[IT=\B6
MTI]G='ML]*Z@[$?I8)ZCH9T6$E'1=).EM'2023U->)]J-!1]'^C@0"^V=I=<
MU264[/V97PF9B\B\S,OYI)D\D=IMZF[DXR1EE4HU2D5.'A4HDT4F^9/HR5@Y
MF0KTBBI,LA"'L\TZF5 %Q]2H#-UW'6VTZ"4H)>DWF[F.2H*PO04R1QQ.JL&6
M45,B %U!1Y>L O>[#7GOT4Z2[/-2M'Y)J>LCAJJ2A$E7%M_;E36R54%4U/)1
M34E;LZGKDD\RJ#%/14OFJN%"!%**=?/Y\*T%X=I7+W4,\TV";%9]4R2<#"YE
M.$)1?O9@QJLS%K-Z;<[<L9%8T=0SQ%=G)9,[?O>4,X<LT'M57MYJ%V%+5TNV
MS$B&2A26)=I.DQ/5>92*ZTU542E6$5*XAD<E560R,$.K8_DY3I$D4FU-A;:\
MGWG%1/%1;>J:7:-=T9\XIHNMEGVY2S02[6Z/['M+&*KI!3SUU%2!6>6@DCCE
MGBZ!RLS7H>=%-87O+R=1G(!^91 Q@3.V?1D@WZH/8B:CUP([BI=@<Q2NV+M)
M-4H&373!1JN@LIW]B[=V;M^A3:&RZA:BG<6<7RRP3B^>FJ(F/60SQ,"LD;@%
M3N!!%_G73+H3TE\GFWJCHQTJV8^S=J4X65%+"6FK:.<WI]I;/JT!@K=GU@;/
M2U<4CI*!(&?K8IE6Q<=C'F/C[,'S^?S\F#$'=[/;?3Z?WXY$B)B)@Y^<>S4F
MPB62EN&+3=R+M!DV/)3EC)"0K J[E1-(7DM,R+")C6P&[L]D7K5DV(JX<))G
M]/56%'2\+T\( '%FC0!0.98V _PQG.C2.?0C.=S\U%4EVMQ"J"3W#'6Z0ZI)
MC_Y!/,'5UY_/GCRQ>]S87NVF8<"1O!-C<;C;%^JLR6)(LQMJ!FM8!MS:7)L=
M+$&QPIJ <=W/7W>':( '#$&103OL+:V/$D>JUC<FP%C?=@+6(6W:8L% UOE,
M8O<: ?*IKNL2=P./=!W>/X^SRX8&YMQ-[;CH./A]>(SCCH!:^HWDVTYC7?QX
M#$>/;*NG.DJY[##!9#E3,$$$BU-*D*LBLX0%5B507"7?"""Z[?NB91<)(JJ(
M]<J9A" U[V!T%Q?0$ V.NZX8%2.8/(VG-OY\ =-+ @W[U(;P.-XJLD@FHLLH
MFDDB05%5%3E3333* B8YSG$"$(4 $QC&$"E !$1  Q!<"X(U!  ) ))*@6!U
MU+  ;]1IVA<S"P(]$AB3J+*@<LW.PR$'U\58!37GH.NO 0WCKPX[AUY;]^ /
MF-LI%MY-K#0'4@D7UM:_ G=B01H"0+@V\ S(-VNI72W,:W.,"*IJ"H5(Y%#(
MJ=R5*0Q3&25[F17N:H%,/44[FHFIU#:&ZBA#Z=4Y1$SC>-5U[7 Y75"!SL2;
M[K96&\6Q :Y"@=JX!%Q=2R.XO:X (3_K*;6UQF(@';NT'AYQX#P#?X]W#40P
M9UUX$7WVT 8*QXBRW!)W $7P%M+V_))TYC0 7%NT00AO9B"!NQIG-AA6DY%5
MIS(((STY'3,M$11Q,#M_'5Y6(0FW:!.KH9*.6GH=-P(F 2FD&_5*8#&$JK+F
MT"MFRELI&N56C0GU22QH>1:^X-:2<N4L0%:019_R0S*[@>J**65N2Q/Q%L;C
M7?IH._Q>8-_CY?+B6D"FQ!.MKC47W<"3Z1 W#B?1!(@,2!I8D*2";$!@+7&_
M2X!TT)MCWRZAQ\N[\_SX:R'!X&^NFAU N5!O8D;B!N.AP9AXBX!/+,=#;4Y;
M7(.XCT;ZV/=\_P ',>/'SX93F%[$:VL>[?N[[CXMB0;ZVWV/C< _1>Q[P<&)
MQ/Q\>/\ AK@P8,&#!CT.(:]N#$'<? XY%M!2)9U721*'Z;9UVGIH''>4I'+>
M6[L D$P$,)@0( "8#"&@Z::B./EG3/:55L[::O2NB.\48N\2R"X&FI-QOM87
M'$[M?IGD_P!@;,V[#61[1@:98<IBRS21Y6D8@W";_1OF)TT%B#C6R%TGVH&%
M%P@ \ U:HG#CH'VQ1X:#KQXZ<L>//2[;@U6IA4 &RBDB('$CT@+7'+=CZW3>
M2_HA(%ST502UM?/)[:VX!EXF^_VX@$GFU=68&[@_:E$!$  8YF8.0AQ2'D;?
MX\+_ !SV[^<0?JD7[7TX[,'DBZ$RD!J&I87_ #R>P.^X^4-].8MQTW8KV3VA
M,T&0&[WEV!=!,'U4-'&X=< W&;C^U#F'#F.(_CIT@UM50#E_)(_VOM]6.S!Y
M&.@+6S;.K+6/H[2J4&E@= 3SWDZZ#3%<RFUCG0S$X-YV++IP U>B3:<..J'H
MX>7$-TXZ0K:U33WM^9QZ>O-?XM?CCL0^0KR=RVS[.KSW?=6K%AJ0!8Z'OUY<
M\01[MK9_M>MW.QPP;] UK$,;< COWMAY?#VX1NGO2-3854&NOXI'KXV;[<=:
M+^#YY,G%WV57DBVIVM5M;?NONW:VW\A;$;=;>.T:AJ!+-"%T'=]BD&(<P#3]
M*" <O<\N(^^#TF&ZIIM-W\DCOOX]J_T^O&^+^#KY+FL#LJON 23]U*FW'07)
M)WCE;CWU?>=M'/RX-(YG.V*(<(1,NE-LBHUF%0%.0;M'C)-0YTFI3*$*W?.2
MF3,(D,8Y3"'6(4<<RMZ>=)*I%2:JIR$<NI6DCWBX%R6[SZ[<SCJTW\'+R6Q!
MLNR:Z[@J?\Z55C>Q)-B#\;AC4*;>NTBU(":-G@P!-,I2ZU*!-H!0   =6@ZZ
M%Y[M^_&=NG_25 JBJIP%TTHX[V%OZ?\ C8$ZXVI_!F\DKD%]CUY-Q<_=6JXW
ML!8[N%_LQ'GG2(;4*!NJG:X -0#C3J^(ZCIIN%GH.GP:AA#Y1.E !M4TN@T/
MF<?#=^5CH1?P7_) 5S'8VT3KH!M>K7=WAB1III<XC;CI)]K!L<2IW"NE#40#
M2DUL=!\['?PU\0]O'%+^4KI4@[-53$D'?1PC=KQS[[\+>)O;'3C_ (*_D==,
MS;&VK8@6 V[6\;[P1W<]>[&B<])_M?H"8$[I6PTUXT6L&Y@'-AQT^'3?QUQM
MY5^F"6 JJ2W_ +%3FVX[ROT'GKI:U\7\%'R-R:-L?:VI.[;M;;37Q)MWCCZM
M \Z5;;,;AJG>*N&NN\:#5Q'<(  :"PW>?CSWX6/RL],V?*:NCM<7M0T_[/#=
MSQL7^"/Y%')!V+M8:[QM[:'&Y_UFN[Z=!C6&Z6;;5)IU+U5BZZ:Z9?54=V[7
MBQ'?PX^??C4OE5Z9$7\\I=3<?R&GOW?DBWT^.&?^")Y% 1;8VUK_ /OVOMQX
M9_;W#OPD/2W[;8";2^58 U'<&7M3$?-K'COU^3#CRK],0+>=TFG'S*+W;OHM
MBD_P2?(N+@['VL1J+?=RNW6MIV]^_3=K;$!?=)CM;/;.K<W%SKAYY5DV8'<!
M1:P5(6[0% 1*#<&0(@8O=3ZGTZQNMH81 H!C(_E&Z3S5'7O4TYD*JM_-( +(
M&RFP7?9C?7$C^"EY&EB,(V-M0H3?M;:KB;VM>_6>W]PQN2]*MMF%#3U<UD?&
M- JH?!W@/N[]=X^2_P"^1TJX5=.+F_XG!^SBO_)/\C5K#8^U@. &W*]0/4)"
M+]^%2]*YMGD$!"\5@1#736@54>(:#^Q^)'E*Z6"UJR#3AYG 1["N#_)/\C?\
MT[7OS.W:\^][>WD,*ATL6VD'"\5;WOZK_H&''E-Z6B]JRFU_]"I_V/?A3_!.
M\C?\T[6[K[;K#;Z?LPJ'2S[:I>%ZJP?^S^J_Z!O\^N)^^?TN'_/*???\4B]V
MZW@, _@G>1OCLG:Y_P#GE:/9VM.-[:^'',.EKVV X7NK>]]4_P GX<>5'I>/
M^=TVZWXI&/KO].#_ "3?(S_-&USX[>KS[WPJ'2Y;;8:Z7NJ[_P#S>U/\GX/O
MI=,/SVG_ %2+X_PP?Y)OD9_F?:W_ $Y7?M84#I=MMX T"^50/'ZW=2$0\PQ^
MF&^^ITP_.Z4^-'']N#_)-\C)))V1M?7?_GRM]GI#3UXA3_I.-KR2LI;<ZNM;
M/.ECT(LKD*)6"I=Y-E7*R28M@8]QZX'=K"93J]8X& #"(%+IDE\H_2B:<5$E
M33&4*%OYI%:POP(.NIW<SIBU?X*?D<6+J1L?:>0-<7VS7$B^\7ZSC8:>.-R7
MI5=LPH 'JYK Z!IKZ@:K\7@_3$_?(Z5#=5TX'+S.'ZU)Q7_DG^1JP'W(VL+<
M%V[7@>H9S;"I>E;VSB\+Q5QW:;Z!5>'#E'AB1Y2NE8U%93\OQ.#]G!_DG>1K
MALG:X/\ []KC]!:V%B]+%MID^UO-6 .P,OZJ(>7?'\?%PPX\IO2T;JRF_4H/
MV<'^2=Y&N.R=K_\ 3M</<PPJ'2T;:P::7JK!IV9?U3\G]N_LUQ/WS^EWYY3_
M *I%[A;V8C_).\C>O^:=KVU_\>5U]=-^:][: @C=B>99],+M05^[P$EF4[KU
M\HB+PI;/6F58@J])NXQ4.Y++Q,O'MFZC639]8KEF#D5&+A5,&KLI$EA71W;/
M\JO2*&KA?:)@K:,..OITB6G=TU[4<R9F1T])=X:V5NR=.!TG_@A>3:NV'7P=
M&DVEL?;9B+[.KZG:=77TL=3'VHDJ:6:3(\$K 12.MI8@W6QDLN5OTW9/9N4+
M/"@P69.6TZVL%5L+8%6SE$Q2.63M,-'\1+,P,*L;,Q:XF:R4>X %6RQ1UZZ9
MTU#_ *)V3M2AVS1T^T:"=)J>I4N&4@%78D-#, 3U<H>ZLKV)(ON-C_-7I5T3
MVYT(VW6]&^D5#)L[:.SYF@DC=+12Q"SI4TLN5154LJE7BJ44"4-<K'()(DMD
MG/S>GT>Z/NXZ?!@>%O 6-M;;SX[[=P./.8INS??0C@_N=C/%^R<L.GC[.8\-
M=V.Y2_\ )<W_ +3+_P#JX_C[,.V\6TW\;;BW?Q^-+VNCRXY&+-XY7'LN.6.)
MAV><XD)^QV-;.-N1">;2;)W$H)S,5 Q@2L_2)R8M4<R9O4@1EG#6B%BV<<\<
M.31;2TS1G5GF3-7 S^>-.IC4.PL'25VO8)D6$R+&&T"3-'*\F8@+UK$ ',QE
MVN^9% ;JZB*-;"V:6&J2-I+6+/'UL14V)"Q*JWRJ#HX_9#G(AM$KTC,5&G*L
M6T9$@[KXSI6L]4HZ,S>(>,>D:2[!-%&U2>8-7G)@[!07;):N"I%2QGS>$E&"
MF-T,"KZ$31F6!LQ$T4:):!W N,[Q#.[9B,[!D9<R25A5 J4():0".*4Y.LI9
M#(^>9?2#RH))2 >R3&G: 8D2179VNYO"+V*S#8.)1H0S6/K,N]L\K4()FJ]S
MDG2T=XW3ED%W5<(US-HD6X.=BR?2<%E]$:M8YIX#80D,CV98BMSV49P66_41
MQ*.!/5NO617)S$*;]8TDF)SJS1L\785(2T*-;*1,&9PY!)ZZ./)+<6229PH*
M!%,2>[)UKGC5Z/5O,8I4Z>SJK9>ENI26LB$Y)TZ]929DQK.U3:S&-<K.SSE$
ML[HLT$8FA$,LS5&4'3H]K7UC6ZU$(?,,H0&,Q@,S$F"2E",SMJ[B.&IIG<W+
MAPS=K,,0REDZIB5=EG$A RJ?.:>M1PJC41+-/35*0JRY3 5C>,]7(DH4V9,Q
M72;9J[S@E%#)S\%*O)I%[:$)21K+!"O-W^6JJ*$VD@E6W+^(D;4G,$<&EQFY
MI6/%!"/*_7EX5,G5!B#U4E [-8$RFD:G:4R KH)DAD4C,RVF.8!599&D<L*E
M19%F2N2-1EM3FK6M6-TW M$U33Y0,H44R%>T$,73V7%?<5:HLX%::+/DCY&Q
M@P?@JJOW&$<668=P$-W9=R[<+>IN$<1]=%95=0ZIHL3F$HB)"S#I%3J2&>.E
MIHF<-<RM%301R3$:7$LD9E! -A(+VS##,0TTSJ0%:>=E2VJJ\TC!#V18JK*A
MUL3$0!V#:<8NP8,&#!@P8,&#X^/CW8Z+K'W/Q'_ D?B''G:G6>;_ -8WOP#<
M+[^.-[BG!B,7+[FI3^\;?Y8WQHI/QB+^M]1Q!^L>_P"/JQQK;LJZU<I%Z_DU
MI9L6<@&]3MT?'.T4(^ZU)JO+.FE:L:2[5RL:,;N9V9.52(<1,BLA*R4<Y?K1
M3]XQ7[?4QYF?*"6>.1KV(9X3\F3I?L@!; A2JA6!!;,'M#4WN&33@K*48#D#
M<M;6SF_ 6A=>V;<M:XLQ,W1E))I'HGC&\1/+1TS#C5PKC>J-:<XCGL6HW=U]
MA#L(E)L9R56;56B6KA_,O5',J,B+"BDG5BR,C%C?,&:E>Y'HW5J. J0!Z!!N
M"1@?M[R1\HTH(-B'>*HA<CEFCJIP>]\P[04A9GLZY=1=D7M<.29B9EUW^V=*
MLGK8S5Q!S%GN-LG*T+%VQ=,T827D[O+D<IM4$'[5JA%DBI".68$7.OF\5R;'
M43!CF-V$[PR2JW<\E/"[6MK&!Z+.K,Y+N7._)2H+;E\R@:FIV4&]F6!WC8F^
M=6(<-I;1UW91RAJL6M$0D2JR:+1E6B!(W95IHB+"EJV8U:([CV->:Q,PX8M[
M4^8.WT]'RKZ=9-8Y.PN995!59Q:44Q]60,GRH(  N)87@<$  93&Y[%LF8!L
MI(Q&\EM]R"/Z-JJDK!E(U'R]%3OFN6LI7-8X1B=D[*B!DRST*A)QME27B7[6
MT(I5I6QL9B)9142G(Q\R[K;AZQ9N(&%C*^:G-54LNX^'9-6T'3HE1LV61K\W
MBRLMM'0(Q.K$=28&)8@DM)&6ZQF)+.S->[&[&1RP9F)8&][ 7RS=>@RJ H$<
MN4H%50 JH;I=3*C9!4I.-HT='/;)$#ES3J[2ZL_9231>0:,*B[A'U9D'"LM'
M2:+V6B7,$B8%G+<[.22>R+::8R35P1%&UQGF><DK([]9F72SE*J(LM[V/55U
M7'K<!9F( <(RJ=8NI8YH[DE3:Q!-.^4V [/6TE--;>9858D@L&M&KUJ(IU:@
MJE -SM82N1+"%BFZJZKI5)A&MDVK8JSIR=5PY6%)(HK.%U%%EU1,JJ<RAA,,
M%%( ([("J%T "H $46L0$4!5UN  +[[P<V9W#N'DD>5G!&8O),T\AU!';D=B
MPM;=:UAB@Y#9HK41'O8?*A.IY?0,U/-K18ZH_I"-MI\O8V<L:<96 L&$[7E6
M$RUD2,Q36;R)XX&<9$LBQ14XF-%MY=.B]!1%XMDQ4M!33U/GU52FD26FGK#.
MU0*HQ QAI^M";WRK'!3QQHJ1(J_49/*OM[:DM-6=+ZO;/23:.S-F2;)V1ME=
MO5&SMM;.V.U$-GS[(6O%+5(^SI:22=2)UZ_SBJJYS/UE75/+7"6QZJB4 1F<
MGTS@@V;%7+D9) Z*W92+298(%=^N[WT1*/F6#*88)D5*5C*M49%H"+U,%\9X
M^A\"%'2/9",L21J4V$B,BI,E3&%9:VZF.=(YDRG29$EN712.Z_ELV@X=)6Z8
M3(TCRR1OTWSP22R4T]#/(\#='NID:HH*JIH9F>(F6BGEIGO YCQM(G92D8B>
M;6%G:,M8R50?*OPEJ_DN>.G6ZKE^22>+QKV1S(G(YJZ5>D!V0SV%E&!7.BB\
M<Y)UTSO'T52GFZZ%MG0SM)UHFBV0$D5PRNSJ[U4O5LS*KG($#2J'8,UL9:GR
MORUE"=FU5+TGK:%HC3M25_3.>II)D-,])'%4I%L:GF=!3-YOF2JIYA$ BS@D
M8Z$RVRARZRC8RC*@5>.@#3SU.4L;] IEI2Q2R:!4!E)F26,=T^=G#NBIC'4!
M$%W#I9-(BCIP93L;)V'LK8L<Z;,HX:4U4PJ*N2) CU52.R:B8C0R/J6(L+L;
M#'A>E73CI7TXFH)^E&W*[:J;+HAL[95'/-)YCLO9P(*;/H:,A8H*>++&@M&'
M=8H\[,$0"R<=?'EL&#$-N/U"_P ?5OQP)=J5*Y@,YN @W$<WDVF:] N#8919
MRV8."Y=9Q5;,!TP7=-&D@X:FE&M87CD71&+L&[ATDNH@JD0Y<>DK0314I6QR
M+22VU&80]6Y4&Q()"V!&FZPTQ4=!*H!/6054!/)JE&6,\!IF%B;>/*9GV?\
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M:Q,="0C1"K!&#$B0TZPHUV4M.M'5TQE !]*6:IBG#'M+)'&R$,H(O)5J@/E
MB%:)RI (6$UM/6" [NRD5+)3V.A4$',"<1FI;+>;D*URY9SF<UAEF=:K579V
MQ./M\JU?S5[CJGE5$S.903-EKES=OYEQ.T6TR -5DXUQ.DOTXZEIMHZ>RJ4E
M8JGKL^Y,YD5!8*N:2"8+E%ET,95P,H(ED"6#O>"6$)4:R,Z!RP)) %6DBDD@
MY23&T:ZE3#VKG)CO3W1U[?YQ_G]W%H%K]YO] 'U7\23QPRBP Y7[]Y)/TDV[
MO9@Q.)P8,&#!@QZ'$/*'SY_$.#$'<? XY&MOWW+_ /X/TC_)IL ^/W0#?CX[
MY0?^48?_ %<?N&/LWDG]#:'C#_VY#I[+'7=PUU@,U]J.G'K?_P"QL?.#N/@<
M?H.CW);?V;?]7%0SVOU0#R$=_B^IX?/CBC'I*3TAK^4/7IOQ34]P-XS&\G]5
M'Y^;!CT%-^3_ +_U?8,4G/#]4?Q!I_\ */IQ7)P]?Q]&/34FX=UO<<5-+<3?
MWP^7GIR'Y\AQFDX<K']^/00;O9N\3X_7B!R'/RAXN0]O/?N#CA,=6#TS_5/U
M8ADCS'QB/'QCIP\7YN6,$OKW<SWG6UA;>/#=J<=B+<.\\;'Z1?U=^NX XA3W
MGI^U'X-/G\6,<N_GJWU8ZT5LVO,?7]=L0B2^W+RW!O\ .&_3GY>7GQ2VX^!]
MV.O!^#/<3S&N;]YUW<N&(1(?ZX/]\;L\>,DOHCP;W#XT[M>79B_!+X+[C]?A
M]>(<_P")_(/HQQY-X'<#[0,;::^;V^RP_=ZL0Z3 .YCRW[N(;NMKH/F#@/9A
M(OPOK7W''3BW^M?KQ'5.7GQN&[UGWG%LGI+ZN-N?Q;CAF?\ 7>?TXG&5_P K
MU_7AHI]H;R8=/2]7L^-WKQGPEBW!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,
M&#!@P8,>&TW:@&A1 VO,!+OT -P#UMY1 P@ ZZ"/5$P"<]=XM[>?AOTOW FV
M%:UA<7L0P-KV*Z[CH;^C8D WL38D'],?0_;,^=F6%<GLWKS/S53H^9$6W-6L
MI7)"@$T03(+L,P9UH[2.>$5[S!1I!(M.X2,HP<'=RARL"1J+G]"^2KH]M;9\
M,^TJR>6"CKXE,&S7N$F !RUT@+#JG5;=0 @:1&S$Y<EOYJ_PM_*5T*Z45]'T
M7V'046U-N='JF6.MZ4Q$&6C[0,^P*254R5,2N"];(\LD-)4Q]3#_ "@U&/N4
MGS\WI\>/LNX-NOH._?P]@X<\?BO%-67[Z$?_ (.QG+3]E)?3W1W?"..]2_\
M)<W_ +3+S_U<?+7#O<Y1X\;Z\O;;E:_=BZ@W"'\V.,;6-]UM>-N^W=AS?*;
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M#5TNTE@)'6PT]3/M"J$'G"7BDF2-94C+=6US8_51  *'5 -P 4  H &@!N
M H#U0X!H&F@<M=,?24R@KVM-;W(OJ"+&QM8'30$<>9Q^96S-Z18M=KZEKDV)
ML2!IOR@ 64*+6 P^3'C[O >6N++:$:7)%K&YO??O[[=V^W'$93W>T>S?O[L4
MY9=^9\>(#KI7(T/%J$G+>4> <=-^[3D..[26.S)>%ZF4\C;)&./LONO@9AF
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M =TNU /Q!7/R1K[N$:HF4_A9#Q]+Z-WUX,B\OI.,?76O?[KM?X KGY(P-4S
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MY1H]PI-\H.\+?7*-+ZVOA8O1 Y^D[CU-H:M$[WC%(5N!$KF4$(=4-%8E$"G
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MC+:)2+JLK, 0. -R%L0UTD>2S?E]LDJJ(LDFP*WS%0A-LH %BH5MZD-U84@
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MY-V$'I-ZOK^._"/O&[=R^/@<,)#Q-_>B/'Q '#RA\O+%3;SXG%L?HG^JWO\
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MD\+D7[]P'.[&RKP)-M,3E-P./:N.*A"02W(:9A_1(._3#<VX.6H;^>[XM_B
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M*6[Y&+6U2=G(/GZ5@M=<@GY=E-O156D(8D6O8"Y)&F\G3'9J;FEEOH6I)UC
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M$[O;BHK7M.;-B\!()(;0F1RZIR(=1-+-BAJ'-U7;<QM"DGS".@ (CIP !'<
M"(;OXN=(;V^X.V=?_NNN_L,*64<1[_=CE&TW[98MS]Z_D<^LKFXS==]1]L:1
MV;5&18W*HE&743K-A06DW/=(]!:=F5&SJ--%S+8).1;H2I&;]\V<2>B_2 K(
MAV!MDHZD/']S*T%BP9<U^H%Q8MZ+: C><HBL5R&1U(#1E61M]F4@@]X!521>
MQL+C08K*1@]B23=R,O)9YT!Y8999!U*6-3/&J)RT@]956<H\>Z>E0F48QR+&
MJ3J\&9FM'&C9)@S9I3K*4ZSX7K2='.DDK1.^PMLEHIEF2VR:P S];,6E8+3V
M*SRSM)*A!5854%<EXDJLJJ\8:R-"U.VO^@D2("-#>ZM3)'DCDNK=86D#*;,&
M<-4]AB 9(1L7G9EPVCHZPQ-S@V7KUTT[6O7N BXN'@;O"H*2PIM)V&CXAHV8
MIG!>$Z@N"N8AP1PH483H[TC6Q78.VAVHRI;9-?= D,<$BF\&8B1(H\@(95(.
MY'F61G?K79V87D8NPN %#3S5,B*-0I>:HF8E I(RYFSI"T6QD8;8@D6)HYSG
M3EH9JXN3:_R939T4]<)BU(-89(TN^3=3#A$C]P\@(R6/(,$V,BC(!(E8O&<=
M-S<?),O1WI)$U.4V#MHI3-3!4.RZYLPI)(77? S97%+"A)WHI4FTCF2'(D2>
M-C83]:<XL"O7+4(P&7=8U,T@   8HV\ 1NV;78K8F:BVSORV*5LT)#'2-G13
M3)/JF@E64&M-?%&8#N]>;HTJG) )13FW*5>;HR$P\1DK 28K/1WI$0H;H_ML
MHJ*K+]RJ_,2@.2W\FW+K<$V-[,&!(+*8T:4J5 DD=M+[IF.<7%BH&=V[-BIN
MR,KA2-LW?;%S:G#1"9QY4&KHNLOG1VI\YJSW=0<M(JJP5<;G>%L)7 LUH6G1
M41/-!4[WL$8M*L)5-PTEGR*LR]'>DDLG6ML';3.\DSR7V37V/7JR."#3ZJ2[
M,1<EEEF!NQSF5E*LQ#6+Y02& -U97S K<*246^4  @95 50(ZPA=AV+8P\=&
MYS9:LVD.NP7* 9W55PO(]X+0CP"2KEY/.G+H7LM6X*;DG15$G[V4CBJK/!;N
MY)N]?[@])@RO]P=MMEFCGLVRJ\LTD*T<:EB:?5G\S220G5G8N#<L,&=1D*E0
M5@B@%E"CJXIJR=%"[D \\=0HT1 D7:$2,;NKF=6S-4XHD+"YY9/HQZ;Z9DBD
M5S6ICA3ON>F)">D3BHK.B?J*24F[433 0*DF<J28%*0N*QT<Z0A47[@;;["(
MESLG:!/9 &I\WUY<?'"W4;B-=3KO/^%AA1YG7LM2,G'SDCFSD"_FXA)VA$R[
MR^9=NI2+0?IBD^1CI!>5.[8I/4Q[DZ3;*ID73#J+ <HB&)_B]TC L-@[< Y?
M<K:%O9YO@NO,>T8;N,X]EM=BK'(YR9$,$5$Q2(=I><L1% IBO$C=R0>/7;$>
MLA(R*!BK-52&1D7J?4 '*W7E>C_2-6#?<#;K:W(^Y>T0&(MZ1$<9X:&Y-P,)
M)VT90[(3^4ABS#_BQR#V93QUX:!?,[9W<H+HNMI_+MP=TBX;NW*V8N32KIVD
M[1:H.B.5S,A.NDY281Y'"!Q,W7(P9)*(F2;)IET'86W3_P#LOM-0?R3LK;3<
M+:E6"DDZZ <N&,PII!J-I5F[CYF#X#^1Z<@=/'&4#F9LU5T[#O+:-RK.WCU1
M529'OF3#=J?>^.4@^#V+%P@4B\D^=D%DX:J Y=.3BH8'3DJRR;$Z02 @=&=K
M1L?RTV3M?-WB\C2J01H05)UT(WAXX6C<,U943  C)*:;(=+7/5T\;7&\68:C
M6^M[ ]D;L]FZI2Y[Y-&$3: 7USJ2(ZB&@!^K@ZB([@[1]W%'\6^D1*_YAVT/
M3N3LJN '9&\M   ;6N;<L:1:[&_  6/$&_#NYXX(I[IN^OUQ>,7*#MF[N%C<
M-';5=-PV=-UYM\JBX071.=)9%=,Q5$E4CF34(8IR&$H@(^'CCDAK*B*6-X98
MYI%>*1&BD1@9#E9'"LK#B" ;\+X[,YS01E=>RA! T RF]M!86]9&G#';:&]%
M'7<'<D^'+ZD!^4 #=RQVU!4*+G36WJ4>JUEN1R\+<EM#8;@ !X90+<K$6'AW
M8R-J(;MX[O+R\?B#\W*2#;3>#I;@!8[]+;@?B^+%]'4;R>^][BY]1(-^%^&$
MM1[1Q3\>P6'L&GAB;#D-=^F_&!Q'JCO[!\^H;\'+N-QW'F.1U.N [QWG7OWM
M[]?'7?A'!:^EK\AWZ_:?:>>"PUT%B->\7)UYBY)UXDG"A1 0T]WAVB(CH//3
MGO\ )NQ4]\QWZZ^.@'U >H<AB"-]M..XZZ#B#??OW$^TE(0$0W>YVAV>+7MP
M[@VT'&_V^.H'L[L5J>9TMQUMPT'QI?'FG;QW;^0CNW[QX[@TU#COT'=I7E;D
M=]_6>/CS/#CARXT[6FO [B""-W&^O=<>((#H.NO ?E\8@&[?J.F_3L (.;<;
MZZ=QW'P/ GOWZXO4=C0\& M;B22+CF1<\"3Q-K(]OCUU\>O'7R\\+8&]P#<$
M'O!W@\P;F_/""^ECR(U MEMEXZ%=,O*VF[!\_G[@8G33NU'=N%Q] ]F"Y-M3
MW:[M;^K77!@Y=V[N\.6 WO>^IUO>Y_Q^G")_MA\WQ!BI@+W%N9U UW7/?8 7
MY #AB.[U>PDCU7)([R3O.,<1);F+6(WBVH*G3O4V/,7&Z^)%^%]-=.'?[L8'
MX!Y?0.$N.8]HPR7S&_+CZL)#YPY^;\_\V"XYCVC%Q!&MC[#]F*DB4DU<[I@%
M$TU-*_%:%.0I]/T!77<8!T'7B(!Q !Y8>B=EJY"CLMTLQ5R+\E.4BX!O8&^^
MQ'.:H TT5Q<Y@1<:@78WU&FITUO:V@MB]U&C4-/TLWW\?T%/?P']KX]V.JTT
MP"_*RWUO\HW=R;V8QA4('97N[(W>OX._#4[1IUA_2S?E_44^P/\ R<)UTW^M
MD_3;[<&1/FK^B/LQ@+)IO_2K;7C_ *PEO'C^UY\\*\LQ&DLIU^>VZQ'/%9"A
MCV1:PMH--VHTWC4X1.R9ZAJT;<-VJ"7#_P#2/G]S>&\:>NFT^5DMOMUC=X^=
M[_LQ<%L#<+J >'$Z6\!<7TTO?&'>++_Q-K_S='_[,0TTMC\K)N/Y;?;B,HY#
MV##4S!CH(=Y-. Z!WLC_ /9BHS2D ]<]QFN>L/ _UM>.)"BXT%[C@/5P.*;S
M?CV0,Z7HR:AK>6!3:-D0$0&&GMP_4!KJ(<]0U ->&,T\\EX+3/\ A$!L[>N^
MO=?EC9$@R39E%\I*YE' \---;<;V%QINOM"-CQ:-_P!(,MZ"/_>J.\>H&\?T
M/0. \=,=E7DZM0'8D@;GOQ'(^'/OL+8YRVS'=;6W+?\ 9C$\9'=40&/9>=J@
M//\ WO"=9(/RW_2;[<66'(>P81\%Q@@.L<Q'A_WFW'_H]WSYZ:*99,R_*/Q_
M+;EXX1P - ![!\>_OM>Z81,7J/UM8;]=?TFVXZ^-,>.X0Y<]-^*R\I)(>0C6
MQSMN'B;X>,*38V)(TN!R!Y6OO/'"98V.(8IR1[(AR& Q#E:H%,4Q1 2F*8$P
M$IBB " @(" @ @.N%,DAO>1S<$&[-J#O!UU!XXG*!K8<^&'1_M0#EKZ!Q7H.
M0X\!Z\'Q\>S#=3@'E#TXH8J"=1O/$8=-Y\/LQ3K$0]?![O\ V B?\6Y^0?<'
M"4PO52@:Z)W_ #;^H'&B7LTX)T[?'2^AW7^/#'02G#S^+L^/\^N.NU\IN/RO
M'3GW<O#QOC$MK"WK\;;N_77VZVTPW/P#R^@<(/J/T@XD_3I[+B_Q^[& CJ!0
M[ ^/Y[_'KA%!NQYG2_K^!W8K<;CSO]!_?IW#"8_KN.G5'GN]SY\]W,:V4W)M
MIJ?5KBR(BQ'$*VGK_P ,(X7$X34Y>?T81MZ[M#S'=]AP8;J<O/KZ/B^/LQ42
M+G4;SQ'/%D?Y7J^O%4-MV=I!Y>I2.W_^N2^"F_' ;BR@7W:;APOQ&^QW;K8O
MF_%DWB[/:]];VMO^+]^F+Y4X;NT/B'Y^/Q8ZK[O7]N,:[AX##53EY_1BK$XQ
M-IH733AH/EX^GW=?'A5O=M.-Q]/V>[NQ6_#3UZ^&[=RU^JV$Q#<;>'/MY:[M
M=?S!OW8K93<FVER<61FZL.( OOW $=UOI]>N$<+@PFIR\^$;TD%];[M.[!\>
M[#=3];Y_1B@D$$7!TYC[<6(#KH>' \#<^.F.<Y0/Z-JWXIA0\?%3EBE2#7*0
M01E0$@W%P#?7=IW<-<:9#\@M^*G?IIOX@</HUUWXZRXE'0=-W'7?O#@ </2.
MF[AH'>/('0@@6 (%S<Z\;G?;2^IU(..6-2+B_#7D?J(/@?#'+F?JF9#V4B(C
M+ +;"69"N6J5BK4P"P/*JZFSP4O'U^HR<6T;O*?W>2G5(U\^GKVFU95^+9E/
M"K*R+]1:.BXZV1I"Q0H$[.CV8!"\>HM)$I,L=R 9%5;@$VN:QR$@&TJL;@F]
MB3=B 38-8DC6US8D#$%CCYL)6Z+8P+"]LD(]2SSU/>YA2V83R!G8J3K<W$05
M$O*\<A9FT<NVNQ'5RDK+;BFL$-624N K:+]>5E4JZ V"_@[JLRS+8Y),]=4F
MG:(@%AYK0>;MO62HJ$1)<A>=F50HR!E>[>:VD4 &-XJ.A6H#K<6%36).CE0T
M<<;2S4P$?41K>&13+,*+R[;,,T7+A_<6]KS&!U(.Y()19_$JYBVI:M/"N"Q\
M4DBT6K2L2,6R18MTF,5WDU(D@"0MT:GRB.G$9<MYK2"0MZ?6PP"-\^4* Y(S
M/E&4NTF4FP,@0Q:;-E[4\C*$#90A+D!;W;)8JHN;E;#?BV1+KIH :<_GRY;P
MW\.08J93<V&ARCU*  #W * +Z  6W#$!AE ).^X&^QW BXL#:X'<3KR  0X]
MGN;QW=@^X&G -=^%RMJ2#KJ?4>/@=1?QQ8A4D@6S6>QMQ:V8WU]*UV-[MQOA
M'$6!WCXW^\ ^K!;PU[Q]/+UX-WS\_P"?X<&F[UV]QMB;G?<Z\;[[83/Q <5,
M5S+J-_=ON/I^GZ@7%[7[[?NX:83PC%0QL0+:"UA8'@+<+$^-S?><&NAUOP/A
MR/=AOV;A'D&[7W/C'W1Q%UYCVC&BQY'V8^A&6OW!53\3MOB-CJQ?@U\"1X$D
MCZ,8'](WW_NQ^8;IUUEAVH<LFYE5#HIY&1"B:(G/W-,ZUZO8+'33 W4(=8$$
M@4.4 ,H"28'$03+I^FO(JH7HYM(C5CMJ7,U@";45$0"1J0+FU]USZ\%6=4'<
M3[OMQ7.PQD_L025/O$GM1WI@2\Q]1G;H>@/"OHY8M%3K!)6+5K\UW4K-_9W#
M,[FQ*Q$* V=,!K*3)VT;$LD9)ZNG&U^FL=911=&:.3S&2J@I5KXS'(CUQJ#%
M(E3$1GBILV6 32AJ:ZU#2*S=0RS!'$%/669LI)!-RH-B#NT-KFPY@BV/GI5*
M/5WM;8VN?6L+EC/9BER_BH^O+1Z4E&]5C'R3J<DBO&C\KXQ495BC$P:"<>$V
MX;RX#.QW>!07^@55;5)4&D@%.DD6SVKI9*A9&C>SF-8HPCQE1=',LQ9^I#0_
M(R=9=<EE*3.0Y",BJH:P8,9-"Q#921&+#*;J'(T0YK*O>S_7<N".968L"TU
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M;X]J2(0YC5FK !0$3?6YT.@% 3#H /P$=P< #ZK4 #$,XL-,H-RQ*W 0*7+
MDZV0$D:7-EN;C%J+<JBDE\P6U[*"7 :QMO =21>Y%]UK8T%:S*A;?6Z_;("
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MC*ITS:,;\=#<::CQY#%VHV9,6J ^IJL!^@HCH$>Z H:D+J!0[_U -XZ!J(@
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MTT.RGGGF3?ZGGQE_3'5THU6RQ:56SDKIAD;)!.HVR6>;5DG=>21!\YA#LIM
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MVD0+)DI*%"\:1K" P6L&8+$JQ@D:*JB^@L>;RVMU@L>=SIIH"1N&5; :#*+
M6&(E(]#UM0RSYU)RN9&3TA(O5CN';Y[9+TY=.EU!U.JNNM1#**J&'B8YA'0
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ME9.63CY#,7,0D891*IV> I51D$V<8BLK%UEPYK"\E:8Y:+F;8Z9.YV7C1E"
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M%KYR#-*T:M8E>Q$T:W NQ!9KN6=Z4#!>V07(C+$7U<0QK(^I-NLE61[$FU[
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MN<4==I7+*C9(J:8(M(]BG6[R5TRD%K36I%HPQ&9)('+6N;)502,C Z/&M,K
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M&H\/'&P/P#R^@<+B,-S\ \OH'%#;SXGWX=-Y\/K&*=8_?P>?B")_Q;G%=/\
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M^.&(PWPN-&/H1EK]P54_$[;XC8Z</X-? ]_$\>.,3^FWCX<.6)QBW"8C5O\
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M"JLHR>.U;1T/8;G'52@9CT6-NDPE*R47/6.'GF+UO%'<NXN%.7(DBYWRIUK
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MB/KUET_N3E0D4$&#MJQHDZYL#I=F5*-20!S&V6':.&-AJK2N7,MF4 EH&(T
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MB7EQ.)BD, B(\AT$>( &NH  :Z;Q^/%Z)8V'&PL=]R;:&UA:^MP>ZQU#: D
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M<)J0M%6D)J-!NV%)65:M2"C+"*L,]0!<[!M""Q __!D=;WYN$4\P6 X$6ZD
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M.,?D?]4Z^(M8CV8U"NQKLLK /=<C* ?7B)H4!Y<_J]_Q^/%/\<>E'\]U]_\
MUPU_ZHWBW'3GB>KCOZ .O%!KSWJ1OX\.%AIBG\U-CC9;CVM4,SR,R];&>6]D
MR=F1ADP%PT5BYA51NH(''5(RB"1S%YF3*;4- QFFZ9]*,T=MN5]LZ@_*VTU/
M$"_T<+<\:HZ> JY,27R-ORL001K;+WD=W'%LEV!MC)PV;G6V;LJU3G12$QE*
MZF83&%,HB8?JQWZZCQU#77AQ["]*.D#*I&V*[4"]Y0#S.Z)A8\[B^XXQ".,-
MH+\-UN-R/ML!QPQ6Z/38A5*/==F+*,X\!$U90-KOY]8V@AY1\8CQ'"?QJZ0J
M3_GBNTOH*B_=I\AW"U^0P_51[\BF^IT!TW\-^MN9^K6*]'%L)J?5&V5LG#"!
MM=#51H8->76 3" A_? (#OU 0'"GI;TC-A]V=H@&]P)5.8>/5QD6Y@DX4QQ+
M^0+\K"QW::@C3N\=^N.Q(V-80T<PAXABSBXF+9MH^,C8]J@R81S!DB1LS9,F
M;8B;9JS:-TTT6S9NFFDBD0B:1")D H>;E=Y)'ED=I)'=I&=V#NSN2Q=F&]B2
M23O%]==]T0UT%M#8@+;7<Q&\$\N[7"^$P8P/P#R_+B"0-YWX,-S\ \ORXI;>
M?$X9" =3PMZ[C%.L?OX/?Q!$_P"+<XJIB#5R@'6R::[^SQ/QZL:93:GU/Y0]
MWCKX>RV.@S[@W\^'R^3QACLL+!O'[!KRW>WQMC"AT'B;?''U?OPV/P#R^@<5
MCZC](.&.\#U^PKA,=- W:>GAZ=?BY8K&A:YWVM?2_P#ANPC@DCCOX=_^ _QQ
M@//<&G5-Z./N=O#R8K.\^)^WXY<<61;CIN4WN#QUM[,(XC!A,_+S^C"-O70Z
M'72_+!AN?EY_1BL[SXGWX="!?U#B===-,5.VW9VD\54CNW_QN7\HCY=_P86G
M/\L!.X6O?=N'T>V^\8OF(\V3O9[>)M;U_N&+Z4WAKXP\O#\WG\6.L_HCQ^W&
M1=P\+?N^WO&&JG+S^C%6)QB/ N_7CSUTX;OS<OA%%T+7TN=+Z7U.*FWG3COM
MX[O'7G??INPF(;C>37XQ^?CUW<=:SO)X7/O_ 'XNCU5AR &XZ6%]=W$>[".(
MQ&$U.7G]&$;>GC]8P8;J<O/Z,4L"00-3]FN+$XCB;?7?V#4XYSE-?7L6U_<F
M%Y^-37X^P,4*0:Y2#^2@/B ;COL-^_&E_P "NO!K^^WJT]F.L>.H]@!OY;@[
M?-N\ODQWB>1WC=H38]QW_N[SCEKH0>\:^'?CF+.A?.U.<GO6U,N6*3RAG%VP
M%8G=F4NY;#'ECB0YTC%*6=&)%V*";HJS4R?U1T1$NN!2H>(R:_RO9)D)&9A"
MLQ\Z!OO0H<D^IM&Q>Q*@8L<-:R$@^:;2"DYK"9H+4]R-5D+W$+#T9+.>S?#>
M.L=L)4\T;(\ALS7K5S/,FU4I!VMG971)LH]:Q"\B$J:#1=QL9//%#S+YI4R3
M84RK)*O8Y8LNLI"QU-@(8%&DIDSJ039%#*3'+96UU$USU:NX:+K,H*BP6ZZ1
M]>K6-1E ])@6NT8N+@ A IN#F9U 4*,5NG*YV0J:BD^3,"[D:1<-%NB0$=8:
M\UGHUW5<IV+.60.VKZ4["21<R'68#FRNHR*-;HND%G'Z\.HJSJ3--G"DE05R
MM%DN!DRU0>C[>ALD+TGGEE#&(5,<4)FC3J3BL!C$K,<L@<$);,&A*U8EZS>2
MPG\U*@993!++(B]8:AQ.LLE,]RYG1[:^'<2=#0RA8,&\XB@WCF,Y<8UQ6 >6
M>7B',;'S,)9;*J[L*IH%5%!C%Q$>R23:E>G?'.9HG2MS*K,31-"+]6 "FTHZ
MCJ_1#)):E:>$BRLRV4H4P,;"D$8(!-0TID8M(#GH.J+*2<K*!4K&1^3G(MG8
M8ZAY\^ Z^Z&G#=PX<],9KG?<\./*V7V91;EE'(8>+CQN"1>VI);GQ-[ZWWG@
M<(:!QTW]N%L-UA:Q%K#<3<CP)U(YXFYO>YN!8&^H%BMK\K$CP)&XG!B=UK<"
MQ'<6)+$<BQ9BW,L2;W.([N%@+=RD$#P! (Y$"VX834Y>?%;>DHMQ'O&GT8,)
MX1O2/C@PV'RCY=V[\WEUX^Y&- (.['T)RU^X*J?B=M\1L=.'\$G@?><8G]-O
M'ZL?'3;4Z6VT[,6?]FR4JF4$!:T:A'U\\G/V&R2+!1](3T(RGBILF,<R.1%H
MS:235N91=PJLX<D7.5-%,$P/]DZ'^2RGZ1["IMKU6UIJ5JIZA8X(*9'"103/
M""[O,,SN\9<Y54!2HN3J,DLXC;*%)-@2;Z:_N^G%!3O3+YOOD;/7AR=RB4F(
M!C(/)N':W"\F?,R5]4BTR@1PYK+>%=+QP(K]W!O**I+ W7!BL[-W$%>NGDDV
M46@<[5VO'#4O&D%2U+0A',U^J("UKU"B2ZVS0*0&&<+K:#,X!NJ76]QF-[C>
M-WNO?ABB!Z:G,@ T]9"D::AN]4\[PT =_P"E!#3>/#3=N#=KCJ-Y$]FL #M[
M:.F^T$0OKK_I./$\;XK\Z;0!!<Z:-:U]QOW:>!X8]#IJ<QP#?DA1].0^J:>'
M3S=Z:Z:ANW!P#CQ"3Y%-F$L?N[M"[6)(@B%F LK"TFA6XRG@ OS0<!K&N3E
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M()Q(S@"F,!$A03U$IP$>YI&%$@CKU4A,0O5(.F)-VXZ966VEB";6;F +*!P
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M _\ HH$-.S3]&Y:COXX9E4D&Q&G/?O\ C2VN$!(W'OX>'Q?QP:9:A^OO ?\
MHH#ES_U[L#W.S%=TXAOHU^-^&[1X@Z\.=[;[#4W]ESN.O@AEKH.A[QIH/!.
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M1* ]*OSW><(C.6^:X/=]&[AK]&[?-FY@7[CJ._NORN=,(G+ECNU/>^?!*O\
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M^O?N]_T82P8JP8,&,1,4HE QB@)Q$I $0 3F ICB4H".IA A3&$ U$"E,;@
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MVEL,&3^3G*E33B9V>7J)2"LJL[L6@G#*<Q"21WL<TL*R=JY5P!E8<+;KB]M
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MT2?1Z#.*6J1G8*1#RQ3(,YV?>U(SUM& %-::^8?*!0XOUAA8;%<DN!8D2';
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MJ$RQBY5M#6Q*+E+!4X '[ME#H$9#?T:VXH<L[:C.FD58FV(VN'.R/&LW[^+
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M=^%Q%K@BF:OOSF(4YD@;G2,8A3&3.+E%,3IF$!$AQ3.=/K%T'J',41$IA 8
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MUQB?[4?-\887%F$@X&\WS'W?=T\6JGTE_P![W81]WQW;N'UVOWXPWZ[O'O\
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M<39N8]GT;]WTXQ[XRZ_<JZ!Y)Z#]-=Q#F/0$/SW@?4>6(LWS@/5]IQB9QER
M (Q5U'>&GU^@PWZ^*N^;YZX3Y/B']H^P890]]&&[B.\<L)]WRW_<FZZ\_K]!
M\-?\'=^OFW]N)^2Y/_U=?']QQ81(0=4]A]F\Z<]^*VBG>4GKN2A$H/,,)@(:
M.[JX4L]=-&F0%!44B$:DJI7)52D$P*'%V8AC=7JIE !UBGZGSDA%D#D$W(6V
M@OIO.[=K[\-,)?-TS%,@(T 8-O(&_0CU#?[+I.YH&NHQ=N'7A]>X?L#D,#\N
M.BYO8F^MSOMR[OLQG%R-XMPM?APN".(WW-\-S.<O=1^M5PU\4W#!R[? .NF$
M[)W@^T'ZL%FX$?3[B2,)BXR]U_4JX[QY3D+XQYP&[W<*>K4#LD\.'OMKA1>Y
M!.NFMSKN &A'/"8N,NQTUBKEO#=I.PNX/X TY?,<5GJR;@,/9W]W></VC^4-
M!N(M>VG/XMQQCWQEWI^I5RU_'L+_ "?]'YD(CMKG-K\@?HL,19^8\;:_'V>.
M$!<9<AJ/@FZ=OZO0G\G<+\C8&SZWY</7B;-S'+46]9UY_1KW8JO-!YE(5K5/
M"T)F(NF-O9 S"/L];;'3>A%3!DU')EZFY!5J"0+E,DD"*HJ&2."I2D.0]4II
MU,6993F=2N4K8'4"]^&NNIXD7X:4$KK)9HP%4AKJ;G6]A;3AQ]F+I1<9? V0
M$L5<.KW)+JZS<,(@42!H!A"! !'3B(%#4>0<,=-2 @(O8#0$BYW:GD==>'T8
MPJ#F[P3<[_$X\,YR^$!UBK?ISTFX;7?_ ,0^/"$@DFQU/,?9BRS<Q?UV]_=R
MY\SA+N^7@@/UJN/+]G(;CR']01#$')< @ZWX@VMOX85LP%R0.5M^_6W'EW6P
MGWQEX(C]:KCJ'/PY"AKIN]K^_373L^#"$QW/9;?;>!AD#9K@@&Q-C<ZZ7%B=
MYO?4]_@GWQEWK^I5R\GAV%_D_KOY[]V$[']+Z,':MO'C;X'T>K&!W&76FHQ-
MR$>'ZNPGCTW^I[T>8<05C._-]'VCG@[7,:;M-_CKIZL(&<9<:!K%740UX>'H
M/^3OIY^3%9ZH$C*^G>/CW_5AE5C<!AQX'=?=O^C%7,G64?KNN2%@\PPF0AXT
MQW!K/7!C10%-QW(H- JA7(*EU,"AQ>"0WU(E(700,L!@%0Y1'#@*"3ERV)4B
MW$'07]@X6NE$Q@&9D*AA8 '->QMW6L>\XNT[B@<1BK=IN_9N'[..G@'TCQUQ
MTF]'B;'77]W>- -/5C*M[<+$]Y/T$::?%\(G<9>Z:C%7#CRFX;Q_VA[.SR8K
MLITL=Q.\<!?EB3F%A<?3?ES-]XW^S"9E\O1 !\%7$==?V<A@YZC^P \Q$/=\
M6% CN1E(M;D?J^/'"DD&QL;:Z$_:#N^-3=,5\O-^L5<> Z_7R%WAIO\ ZW_)
MY_&&%)C%QE;CQ'MM\<L.F8WLPT4D[SH>'^))'=A/OC+O]RKG_#L)_)_"=C^E
M]&#M_P!'Z<)G<9=;M8FYCV?7Z%#LU_K>'T^;"MU=Q<.;Z</M[\%FY@=P%_><
M(G<9<:;XFZ#S#Z_0?+_D\''ABOY(&UGT-MX[_#X^EU#7N"NG,'ZCBMV[O*4<
MVBD+!Y@A,#7&!@7&RUP8WO7OF3!,AFP54')EP."HG4[Z ABBF )@)3B<@ZDU
M-D5\[ "Y(L.\;R#J/?OQ=+UWFZYF7*"VX$,=U]=UM;<>6[%R'7H <8NWCP_9
MN'XB&O[@]GPXZ+VL+CCP-N?=C*H:PU%M_&_.V\?&F["!W&7N[6*N&_LFX;\@
M[O-BOL\C[1]F)LVEK:<[_:;^O&!E\O- #P5<-./ZN0W/3M@!\7N>[ R->X;0
MVX'=_CRPA+#?;B-">!(Y@X3%QEY]4'@JX[@W_7V%#7G[7]>?'M'%9,=R,K<1
M>X]WU8L0/9K,-1?6Y-K>S3Z\)]WR[_<JY\_V=A?,/W/_ ">??JO8YO\ ]7XT
MX?3B.WS'Q;XX_8F=QEUNUBKF/'3Z_0@>8?L>Y[OGQ1A%<7#7/AW#G@LW,>SZ
M?C_!$SC+@--8FZ<P_5Z$W .X?ZW<5DQ $E7L-=X/@/;K?GW8=0QU!&G<>-QS
MX8HN1>9-!FRL16 S*-,>#8D1<)VNL$C12$3]Q*#4U04<@H7?W0PNQ*?=U2DT
M$35**852C++UI"L#=<EB#8'6^FO \/ 7L)NJ6[)E /!LV_7?;U>WECI('% $
M/U,M^NG[MPX\@T_8+3W YCH' ,=G7?;<.'TC=?PYV&[&#>=]KD=WK[OJOIA,
M7&7X#H,5;MW]NH;\@8K:V8Z'V@</ XML>) \+_:/9NPD=QE[SBKAO[)N&_(.
M[S873D?;^[ 0W CZ?M(/KQB#C+SB$5<=0_MY#<]?[0_ &H^(<*Q0:$-8\B/L
M&(.?^CQYC[-WCXX3%QEX @'@JX!V!X=A?@UK_/W.6(8Q@VRMIX#W8A;FYWZV
MUN;#?IK?E<<=+\< +Y>;OK5<0XZ?7V%X?Q?X;]W+AXL+>/YK>W#)FS-8@6%S
M<:$'A;UZ]^$N^,N_W*N0?\>PO\G_ )>(^+"]C^E]&#M\P?&^OQ\$X.^,N_W*
MN?\ #L)[OW/<?%@[']+Z,3VN8]A]F\Z=^$U%\N]0^M5S_AV$W_\ P\.GE#X@
MTPK=7F6X8ZCB/LYF_P!N(LW$CV7^S=\7PGW?+K7?%73R>'H3X_4[O^#R:X1N
MKS'1CZP/7QU]=L%FWW'A;3WW.$>^,M^<3=O%I/0?PCZG0T]. F+D_M'VG%P$
M@_*7U@_;?';5!%F:FUPT>1RDQ&+;BU3>*I+NB(Z#U2KK(HH)**!OU.1%,H\B
M!C?%;JUMNMIZB<97OF-]]]?@X_*QTVM8LK;:QC[:ZK\TWJTMEI4(J+LBT8^2
M@I&4C7$XI(1S*6%'O!S(,4W#<[MHBX47;IK(F62*15,1_4/D<JJ=^B\E()X6
MJH=I5<DM.LB&=(Y%@$<DD5S(J/E(5F4!BIL;W&.?5 AU:QMEM>UQF!8VX=VE
M^\;\?-N)D[!F%..JMEG5;$ZON9[=O!3C5G-GFG%A(DLWF7T/7XM.*C5(V+D'
M\0Q?JL'CZ;6;-XQM'M7J3'OM-U[^:*EV=3K5[3JZ9-G[,=JB%Y81"E.6+1I-
M42M+())(Q*R(Z)""SYV1G"LM><OF"KVY+ ]H6/\ 1%P +VXG2UAIICHNJY!;
M>5.K*M0@LC<Q$:^O)2DRJR5JRBH'EY)K H(2I5>ZE42DH)W6(.7KK] R3J'E
MV(.FZO57=(K>?JND?02LJ%JIMO;-:=(XX5=:Q05BC>9VCL-,DRSRQ5"&ZS1.
M48:*1*0SH&4("'OG#%#F!%K&YU ](#@P#;\>N-GC;1=#8R.-EZP'9W%TE(VR
M,)2Y%O&SLLW>&?LI<S5K*(%A7[!TL_%B:L&@F[9K+S$<FW",DG3,ZKTCZ%(*
M?+THI0U(N2DD\^C,E-$8^J:)6:,]9&Z! XJ!,2T<<A;K(U<.8YR6)0$N"'N5
M[88JQ#=KBR*YM:[ $X9SVS9MJV!>I.%]F^[,5*.UBV5;2CJ[-),8YE$&(L@V
M;Q+B7=1#8KM\525E56;!JYF)AR]E9)=T^?.UUGI^DW0JF%4%Z2T+^>M*]09*
MN N[RDW8RK$LI*(>JA#.RPPJD4:JB* KPS.@0Q@ "UPR@D6(ULUCH=]K]E==
M!ATWV>-MDB]J7?[-=LFBW"]0N8\PVE:C(':&M5?4M9XUVB@SDF11:$"Z3Z;B
M+<]\Q[M)RF1RV4!NF(*W2/H212"/I-1P&CHYJ"%H:V-6\VG%*)%9GC?MGS2
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MKUTDHF<2ED9!!4J;L%H"<9I)'>1;U%"8HY)98X5&LB5#EAJ%$-!/7C0#0O%
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MA'J"W'MTP]0/Y*A/,6]K"WL-_7B_5.7G]&.HVY?7?QTO].,:[A\:</HPU/\
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M4BC"199>MDD6(R+([21) LC]*-72#YJV?-C]U;.VZ+ILKU3$[J@NF59)0"&
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M!;->;.+BX,\<T;W&I3LRLO:L-T8)6-"\LH:R&]HB"MA?-=W4#0:JQA5@U\K
MF8'*[96WK2Y*4BOV[*M[,OU(S-J$A:%.UQ[(-Y!^Y2L$+9*U$/!3919GT6>>
MBXN7C4)!]W* 75KB@((IO$)([I(\Q2"F49\@A>%3H(QL_9<$9!9@ 2]/L592
M&-W4F(@&0# 2H=JFV7.*E9#JP8[1VC5'LE2=(ZK;1B!6P6ZN2$NV(W8=GW+Z
MM/+)9;1/.8K+MW#94I3$3#0=;@_"]JHN9=GN<)/SR%/IT>515.S6*LJMU(%M
M&'>JQ1TK($E&&42,LF6>&2GE%Q+%%$K,?P(*3T\M[[A_*%DM\X!@60,Q=7ZE
MHYHSD:-I)B=X<2&F=%L!H0M,T;'<%?*2'L Y1V.\K8B+DD8%)RI)N*L2O(NK
M.TK5D3/X)!^XJCM525K;M]%NJU,2+V682%7<P4F+MT99V[='91/>%.TY)*Z/
M:):T;UT56C7N5229:H7:WI!6GE=T&9K BQ.'H3'3U%$]V>.EGHW)4[X8C2QE
M@=P)@@B 8]E="QMA$=E6@V>M%C+/-W*1FAC/4W.V=(D5 6!ZBVJ<13'D9'3"
M=3CI)E5UH^&2!9A#*-H>U$44-9@LK4Q$T]E7,))ZHQ)9*FJJJDH2 RR5,A#,
MZ@W&1<L91K-V2ULIN<M,)(H*42-G>G@HX0P(*KYL!-EOH#>02.6&BE@C$%M-
M^GLJ96MV$I',D'C#PA8)BR(RS&,IC>V0TG8)F8L<TM 7<M2&Y1+A[-STA(HR
M;>>"9B%3IHP,G%-2 AC.9F9TD/9$<D<F4ZB4HDBQYE(*LJB1Q(KC+.K%'S++
M-=TCZM&0&YRM'FO?(6>)G*DV(+F%"A )B90P"L(Q$_S!V:Z'F5;4;C9I&U*/
MVRRKEHT;OXL63%96J2E.<$CUGL,]F(]BXBI9TX<0K&50@EID FU(P\DJZ<+K
M#*8)$D0%S'5T]<H)WR4M11U4:=H]G,]#$"H)5'=\K92;6R+UU/+3M94EHZFB
MS@6(BJ*>>F=@%W$)42$ :Y%4"WHKDML[4L\XK.H2UK9J/+; W.58-I"*&/F9
MBL9F6;-F!!\5S".7J+./MMOFQ!",>QYG<8JW9OU71V;5=.J%VB,=MT25"J=#
MK4T4FSY-+C?!+>Y_U8-BRHK1(!)UA;?-YJ&YKYK4PU<9)L;@5$*/8'=F[@5)
MW9WHUA<S*S]Y8P0E']CFFC!!]'$9UZQ6P\6M-V&$%2)5=^$73N*2>E0F'4Q$
M(.'3\J,85NY% L*S1K#E&8TLJ3PKNN\5:FT IN;=NLC2<LUK =6; 7-A8%G8
M$@R*4F/&3/2M1%K]U)(\;C3-)E<9@#;3S&RUEI-R->EWRDVK)U>9OM@AG#KU
M.RK=&5S(M<_;;.Y<1$W7)2#? L[M,['LTGL8NDQC7OZ 0))NUDD8!96:P!#)
M#'=M0$I$J(X@!OM.M01(;9@L:BPNP, V0*&*Y7D=2!K>44ES_6B-&ACW#-(2
M3V5(M6B9?US+:&<UZK-N\HI>:EYPK,B3)LV:.)EV=XNTCV<<S8,6,8U,<&\<
MP;-4T63--%LEJFD0 KF=WRJUR5>1\Q([33SM42,?]]VWVW#?8'$ @ #3T446
M&X14T-*@U'%(%;CJW W&)I@?>/#ZSA<8*;B^?Y<)ATWGP^L81 >(:ZCSY>73
MR>?QC@Q;CY_[268=PR[S'3?T^9/#.WD:T3<+$:L70G23:IB4O4?MG:0=7NI]
M!*0HZ&$1'=ICZ5Y,]A[*VW5;:&TJ1*KS:*C:#,\JE#)YPCVZMT]); @@[M".
M.?:$CI%396L"6T ))8-8>XWX:#>=_.[G:NSV(&Z_.=0#]QZWJ ;M0WPXAXA[
M.SGC[%_$3HL=3LJ, V!)EJ3PX?+;]-_NOCC&IG!L)00";64;MP^T?3RQ$I#:
M_P _4 ,9/,1R00[8.L"/8'&%'@&X.T W:[QQ/\0>BP6YV5'J; =94GGK^,+R
MOKX6T)"FKG-[2 <;D"WM\>/$Z#<<5W+[;NT6VZW<LRW)=-1_4"ICV!S@AUY\
M^'#<.^6Z ]$PNNRHR=!?/4GQ.M3W8=:B=Q</W7L-V_OT%AO%Q[3BI9WI =J%
MH!A0S7<DZH#I]C5+,&[A_KE<,'$=/-Y<96Z"=$SNV5$="/PE0.&G:Z\G0ZZ@
M@GEBWKYAJ) 2+<"/COT\..+=V5>E6G(J^!3=INR(RM2LSM!O%Y@GCHN-6IDD
MH)$$R3:4.RCVKBL.1T%T^%J=Y$+F%VH=:/,X*U\;TM\GE$*,UFPXGIZB",M)
M2"8N)UM<&!I7LL\=FR*6!<2'1K::8*I\V66S!B+-H I&X:W/:OX @7YX^^[9
MRV?-4'C)P@\9O&Z3IH[:K)KMG39PF55NY;KI&,DL@ND<BJ2R1C)J$.4Y#"4P
M"/Q!E9>PRE)(\PD1@5=6!LV92 <V:Y:P(S7(TL<;+$,,W,:\-]]^[XW#=BH,
MX _2=*_PYC]- U_86?#3=P]S7L[<9JCTZ?CVE[K6('OOX]^-<.D=1_5)W^)]
M6F+_ $/Z30\:"/;R(7S<_GOQV!^#7P%]VXG?SWBWMTXXYR^FWK]XQB?[4?-\
M887%F$PX&\WQ]O\ /\>%/I+_ +WNPC[A\<OCAA+@(ZZZ"(CJ <-=VNOG'3?N
M[-1TQ23<D\S?#QD:7X+P.HO87^WZS;"6#!C _ /+Z!P8,-S\ \OH'%#;SXGW
MX=-Y\/K&*=8_?Q>?B")_Q;GEBNG_ !J7PC]RXTR_B_\ O#W?'UXZ#4X<N/+A
MSX:\,=8WR\^UO/A;F>(MO]^,*[A\<+^[7#8_#S^@<*-_J;W'$GAZM/6+>SCX
MX3'@ =GI[/GQU\@(/2;U?7BM]X/B/9\?%KE,VNIMVF[CIO$-WB'AP'AQ\6N*
MFWGQ/OQ9'Z)MKH;]VH'+UGUF^$L1B<)J<O/Z,(V]/'ZQ@PW4Y></BQ6V\^)]
M^+(^/J^O%4-OOW$_P4CM?^>2^(I[^>)X:=VG=WZ6UWXNF_%A_6?_ +OQ\7Q?
M*G /-PW<L=5]P\?J.,B[AX#W8:J<O/Z,58G&)OUN_@ <O<^?RX5=[?UC\6^/
MHQ4_VZWOXBW#7XX82-^N#=NY[N ZZ><-X<-1U#AKKBIMY\3[\7)Z)W;A[CQ^
MC<3PTWX2Q&(PFIR\_HPC;T\?K&##=3EY_1BAO1/ABQ./J^DG'.<K]^U;\4PG
MQJ8I7\>7^K'[C\:^[&E_P \&]_QXXZ#:T"CL;O,YF,ZI -<P;%6X6HSET0BV
MB=EEJQ77DI(P<"_ER) \<Q48_FY5XR9J*F027>JG*77J]7T T#*F@=NL9=UY
ME&1&ONME.:Q.EM;7 QR]"ZE]2HRASH%0[P1OW7!('?WXY,?Y09 %?"JOF7)1
MLNSS:K]O.["4AV;\DG%W)&]>I9T5>% R]$GYEA&JR!EBG8KK0</(,Y=O*1#5
MZDB*S,A34&2696]%2[4%#L_*MK971:2FD <*5FE!:R-K=+F*2+(P"V[7!E_E
M53M&S7)S"\TT3A;D0H5L'0@;^/RZRB9Y;V:J2N:+F39SM*J&S"ZLLF]@(J2C
MHU1JZ@:+6HYNC%,HX;#,GOZ#R+>*L'A[,I,0SQJ#J+/&I !W#T\P0YUK*>K6
MPWR4J0U)CRD%@46G228-JA8R-9"&PH!4268CJXV#H39U%2LT69B; HW6NL;#
M1A'E!+*P$WC]GBIL;M6[P::GWKVGVFP6BNL' 0W>316T(YA^%6+I5*)3D)1N
M$CF7.R3%R]>*OV*J#!)!WW,\KX4H!ZGJAO,:01$W.H@AD@B8WXQ+*[.0,\\C
M9Y"^1+2X+J$)LKM+)(1I9JJI@GJA<;PQIXBBZI%9A"%S/?:/\E*Y)R<D>1D)
M1]5IBTK7:4H[I.*7@'ME<Q)8A9RNL>.-+'C5>YEESQ1I$6WAHH.NL#4>\!@$
M)$D0LMHI(U=;]9":N64U+H=UV%34NS7+=7*8U5BQ "P<A[:ED9T:QC<TY_DZ
MN-]D:.GF4J"5>,, 6&-'";/-;A8G+^'-/S\V%"<SLFE-3Z,!)VBP3=B5>K3,
MI.6(\,F^,27-(KI3<7']X14TR(VC'[16,1,R6EY6<YSE#-$(K*"!&#VI78D7
ME:65GD=6O&)':54SZ-* =L+FRF1&[=KE*=U,,8M<*L<4<4(D%W>,,C*+@X8U
MW9OJ%<E(Z3;24H<C9Y 2,A#HM(&+@)!Y4)JRV&G$:Q$7$M&U>C:Y-6V:DFD5
M7@C63MXJBYDR/%RN%'576,JJ42[QB0QW(NIGAD@J <U[F2GF:%3?LD$DV;#M
MJKJ"1G=,W++!/#/&!8;G:$ \@1<6&CFM;.U/J]I0MS&3GU91',:T9DB#A2*%
M):3M*.;"+N*6.C&).3PC,V<%B78-N[@X278Q1U72PD?=_2)'0%!VE'7)G&F=
M9$HH0UB;_@MGPV!%QG.EP0).5F1B;6A@@.AN%IC6LC<NT:^6^A-D%]X.(J]V
M3Z(F@/J;DY.HR3Q&Z-+#,P4?76DC;HZ^9A1&8L]&6EVA#(/)5DM(Q"<0*1G*
M1G$ \D8U\J\(^<G4K#%%AB ND:4L*H;&++2T[0+)EWYVSLS7'IJAT%\3(^<L
M^@E)D;.+[I9UG8#0G.K*$N; QE[$DC'2D<S"/CV+ IB'*Q9MF93IMV[1,Q6R
M)$0,FU:D2;-2"! $K=NDF@B71-$A4RE*"2$LQ)-SQ/,G4G>>)Q4.&EB!:^EM
MP%AQ   &O(<L*X3&G'T(RU^X*J_B=M\1L=2'\&OK]YQB?TV\?#ARQ.,683$:
MN&ZN27]ZVX\/Z<;]FN#!C@_,;:%J65UK5J]FBYU0J56;6H9&(;)/RD9!'9B3
MLP=PW,LV,@W@:SEC8YMXOW<ZSPB;>+BV;V7=,F3J%N6?>0EE.EB00DA/.RI\
MF!>Q%S<"RA@C755&9Y75$4:AI'ZL(I)( ),JB^X:ZZ88WK:3I5"NL/6I1=BO
M#/82US,M9F<FH^"%4I\7)R\K$*Q47&22JTJDQBW"IV2[I@N30J!4U7JC5JY3
M,W7M3,5+J:2.$ W,\M6M7''$H.4*[U="\<=SVGG'HZ$Q8,L+*=)%J78'THXZ
M>2B4R$"]QU=8)6'Y(C87-[C&1VFZ%&3KZI.8JW'N+"0@X)W563"&?RS6SSQ*
MRLSK#M5I/*Q+&1(UNE5>"_?R;6MN6LPJK&SS\8"TE@[C=@S:%8ED)8GL@QH9
MWS->RA8XV66YS+F(56(NQE8JK"Q)**R+<N'DG%/& N]@\A+9E&5$,99@6(#)
MAM;9-22L:DQF)!4\RLP/&)K-6K*0=Q#]K!.?5(6 ?R+6R)0R!;+ @'?$,C)R
M3621F8"-EZ\"LNE 4D#BUY03RZN58W9B-T8,B@7"L8YDFL(2&52"5+VO8Q@#
M2Y,L;R(BWN"Y6&4 @E0\3PW,JE!KS;249)UR>O-;RXG)\L);LIZ15Q7>P</(
M6.)SQD,NDH.R-'4@N"<177*-R@I=PR576EEF[!%"0BHZ:;+QD<$]7;-HK=8C
MVO>-5#9R=UF"(QL-%NMI,ZG**Q?K ;W6-I5W$.X4M&0 20JH6'; 9K$.EB%9
M^GM798J5V'M1F=Q1AIQM!*1:YX%,RSB2M%=0NE:KQVJ$@LZ0GYNDNFMN:M'"
M:2#.+=(-95U'3J@0XNR.LKTR@/."T>0$ ,R3QTSAB<JHJ3RQD&^52SLI"QL4
ML5=1KE")<7UZI<A8,UKDHT<<RJ1=RZ)G :1 T]R[SDK694C(14-%V>/D(AB2
M1DF\[%H,09ME9>8KB!ECH/GJ0"XL=8N$(V*0YQ<N:E,/4"J0;F"E9E0))(>N
M0GJF<*&:ZW5Z>DJX@R-9U:2EKJ>8J5O&'ZN3),KQK#J49D;1P64@#K"MI3!O
M2ZG+*DBL06!R!H^L1T?'.MYVPY.E36944YH35)K69.6:TV;L,Q+5R/LK>)K\
M\5402]3LF^DSA=:;;&CR0@6[BMP]72CY2;G8Z1,K'J:%A5@""-VXDBQ%[@$D
M7UN0;<?#'M*7HG3U5)L^45_XQ!%+610PQSSTQFE3*[QBH4Q]9331]5!/U=5/
M.DT<4+*H<QZ7VX&9T&2#!*D5>=<NJ2NA#62;=S+B8C;,QD;(\BVIQ]1;6.L(
MTJ/":K"C=Y9&%DF732GI$0G'3<IH, L>WHP-P6W.0>V!87-M#O[(RG+BY.AA
M",SRU-13"&I!J(46GIX7CECI^O>-C/-) M7-'#,KB#(B25;9:>\BJ*[=R#=E
M R*V5#QRUL<I*14.:&O4'*'EG4#7ZM9)%I#*#'-&$C+236XPT93X<KU!]8+
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M;VZV5IY WSA)*[NP.A+M:P)&()6P%P%5<BH",J@*L:D#?F6)(X@222D:9LS
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M(F9N9EI"(IK&0DIV5ELN*7)OYUZZ6F'3^#3=JO3KO)!1Y N#'8E5ADCFB10
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+#!@P8,&#!@Q__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
